documents incorporated reference incorporated scheringplough corporation proxy statement nual meeting shareholders april part iii table contents p age part item business item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report internal control financial reporting part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules reports form k signatures exevi revised form employment agreement exexi severence benefit plan amended restated exl retirement benefits equalization plan exn cash longterm incentive plan exo longterm performance share unit incentive plan exw summary director compensation ex computation ratio earnings fixed charges ex subsidiaries ex consent deloitte touche llp ex power attorney ex certification ex certification ex certification ex certification table contents part item business overview business scheringplough company refers scheringplough corporation subsidiaries except otherwise indicated context trademarks indicated capital letters k property licensed promoted distributed scheringplough corporation subsidiaries related companies predecessor companies incorporated new york new jersey stock predecessor company became publicly traded scheringplough corporation new jersey corporation incorporated name schering corporation scheringplough global sciencebased health care company leading prescription consumer animal health products internal research collaborations business partners scheringplough discovers develops manufactures markets advanced drug therapies meet important medical needs scheringploughs vision earn trust physicians patients customers shareholders serves around world scheringploughs worldwide headquarters kenilworth nj web site wwwscheringploughcom april board directors named fred hassan new chairman board chief executive officer scheringplough corporation leadership new leadership team recruited established six eightyear action agenda plan directed toward goals stabilizing repairing turning around scheringplough produce longterm value shareholders new management team reorganized business one managed along geographic lines primary segments us restofworld business organized around products currently major product segments prescription pharmaceuticals consumer health care animal health principal products within segment follows prescription pharmaceuticals organized categories follows primary care including allergy respiratory clarinex nasonex foradil aerolizer antibiotics avelox cipro dermatologicals elocon erectile dysfunction levitra copromoted glaxosmithkline plc specialty care including antiinfectives intron pegintron rebetol antiinflammatories remicade table contents oncology temodar caelyx intron acute coronary care integrilin subutex suboxone cholesterol merck scheringplough joint venture zetia vytorin consumer health care organized categories follows overthecounter claritin afrin coricidin ad ointment correctol drixoral gynelotrimin foot care dr scholls lotrimin tinactin sun care coppertone bain de soleil solarcaine animal health organized categories follows livestock banamine nuflor poultry paracox univaxplus companion animal homeagain aquaculture aquaflor slice scheringplough operates primarily prescription pharmaceutical marketplace however appropriate scheringplough sought may future seek regulatory approval switch prescription products overthecounter otc status means extending products life cycle way otc marketplace another means maximizing return investments discovery development segment information scheringplough three reportable segments prescription pharmaceuticals consumer health care animal health segment sales profit data follow consistent scheringploughs current management reporting structure established second quarter prescription pharmaceuticals segment discovers develops manufactures markets human pharmaceutical products consumer health care segment develops manufactures markets otc foot care sun care products animal health segment discovers develops manufactures markets animal health products table contents net sales segment ye ar e nded dece mber dollars n million prescription pharmaceuticals consumer health care animal health consolidated net sales profit segment ye ar en ded decem r dollars million prescription pharmaceuticals consumer health care animal health corporate consolidated lossprofit tax corporate includes interest income expense foreign exchange gains losses headquarters expenses special charges miscellaneous items accounting policies used segment reporting described summary significant accounting policies included note item financial statements supplementary data k corporate includes special charges million including million employee termination costs well million asset impairment charges million closure costs primarily related exit small european research development facility see note special charges item financial statements supplementary data k additional information estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million corporate includes special charges million including million employee termination costs million provision increase litigation reserves million asset impairment charges see note special charges item financial statements supplementary data k additional information estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million net sales geographic area dollars n millions united states europe canada latin america pacific area asia consolidated net sales table contents company subsidiaries countries outside us single foreign country except france italy japan accounted percent consolidated net sales past three years net sales presented geographic area companys customers located dollars illions total international sales france italy japan net sales customer dollars millions mckesson corporation amerisourcebergen corporation single customer except mckesson corporation amerisourcebergen corporation two major pharmaceutical health care products distributors accounted percent consolidated net sales past three years longlived assets geographic location ollars millions united states ireland singapore puerto rico total longlived assets shown geographic location primarily property sales products comprising percent companys us international sales year ended december follows u internat ional dollars millio ns remicade clarinex otc claritin nasonex scheringplough net sales include sales vytorin zetia marketed partnership merck company accounts joint venture equity method accounting see note equity income cholesterol joint venture item financial statements supplementary data k company disaggregate assets segment basis internal management reporting therefore information presented table contents research development scheringploughs research activities primarily aimed discovering developing new prescription products enhancements existing prescription products medical commercial significance company sponsored research development expenditures million million million respectively research expenditures represented approximately percent consolidated net sales percent consolidated net sales approximately percent consolidated net sales scheringploughs research activities concentrated therapeutic areas allergic inflammatory disorders infectious diseases oncology cardiovascular diseases central nervous system disorders scheringplough also substantial efforts directed toward biotechnology immunology research activities include expenditures internal research efforts research collaborations various partners several pharmaceutical compounds varying stages development predicted compounds become available commercial sale companys product pipeline lists significant products development available scheringplough website global operations nonus operations generate majority companys profits cash flow nonus activities carried primarily wholly owned subsidiaries wherever market potential adequate circumstances permit addition scheringplough represented markets licensees distribution arrangements currently scheringplough business operations countries approximately employees outside us nonus operations subject certain risks inherent conducting business overseas risks include possible nationalization expropriation importation limitations pricing reimbursement restrictions restrictive governmental actions economic destabilization also fluctuations foreign currency exchange rates impact scheringploughs consolidated financial results additional information global operations see item managements discussion analysis financial condition results operations segment information described k patents trademarks intellectual property rights overview intellectual property protection critical scheringploughs ability successfully commercialize product innovations scheringplough owns applied license rights large number patents us countries relating molecules products product uses formulations manufacturing processes assurance patents scheringplough seeking granted patents scheringplough granted would found valid challenged moreover patents relating particular molecules products uses formulations processes preclude manufacturers employing alternative processes marketing alternative products formulations might successfully compete companys patented products outside us standard intellectual property protection pharmaceuticals varies widely many countries reasonably strong patent laws countries currently provide little effective protection inventions intellectual property rights traderelated aspects intellectual property agreement trips administered world trade organization wto countries agreed provide nondiscriminatory protection pharmaceutical inventions assure adequate effective rights available patent owners possible changes agreement made future diminish delay implementation developing countries soon assess much company impacted commercially changes product patent expires patent holder often loses effective market exclusivity product result rapid sharp material decline sales formerly patented product particularly table contents us however cases innovator company obtain additional commercial benefits manufacturing trade secrets laterexpiring patents processes uses formulations trademark use marketing exclusivity may available pharmaceutical regulatory laws scheringploughs intellectual property portfolio patent protection certain scheringplough molecules products processes uses important scheringploughs business financial results many companys products addition patents compound scheringplough holds patents manufacturing processes formulations uses may extend exclusivity beyond expiration product patent scheringploughs subsidiaries licensed rights number patents patent applications us abroad patents patent applications relating scheringploughs significant products including without limitation clarinex intron pegintron nasonex zetia vytorin material importance scheringplough worldwide scheringplough sells major products trademarks also material aggregate business financial results trademark protection varies throughout world protection continuing countries long mark used countries long registered registrations normally fixed renewable terms patent challenges hatchwaxman act drug price competition patent term restoration act commonly known hatchwaxman made complex set changes patent newdrugapproval laws us hatchwaxman drug could approved without providing us food drug administration fda complete safety efficacy studies known complete new drug application nda hatchwaxman authorizes fda approve generic versions innovative medicines without information upon filing abbreviated new drug application anda anda generic manufacturer must demonstrate bioequivalence generic version ndaapproved drug safety efficacy absent successful patent challenge fda approve anda innovators patents expire however generic manufacturer may file anda alleging one patents listed innovators nda invalid infringed allegation commonly known paragraph iv certification innovator must file suit generic manufacturer protect patents one ndalisted patents successfully challenged first filer paragraph iv certification may entitled day period market exclusivity generic manufacturers recent years generic manufacturers used paragraph iv certifications extensively challenge patents wide array innovative pharmaceuticals anticipated trend continue employees approximately people employed scheringplough december marketing activities competition prescription drugs introduced made known physicians pharmacists hospitals managed care organizations buying groups trained professional sales representatives sold hospitals certain managed care organizations wholesale distributors retail pharmacists prescription products also introduced made known journal advertising direct mail advertising distributing samples physicians television radio internet print advertising media animal health products promoted veterinarians distributors animal producers foot care otc sun care products sold wholesale retail drug food chain mass merchandiser outlets promoted directly consumer television radio internet print advertising media pharmaceutical industry highly competitive includes large companies substantially larger scheringplough substantial resources research product development advertising table contents promotion field selling support numerous domestic international competitors industry principal competitive techniques used scheringplough products include research development new improved products varied dosage forms strengths switching prescription products nonprescription status us many scheringploughs products subject increasingly competitive pricing managed care groups institutions federal state government entities agencies buying groups seek price discounts rebates governmental pressures toward dispensing generic products may significantly reduce sales certain products become longer protected patents data exclusivity arrangements fda government regulation overview pharmaceutical companies subject extensive regulation number national state local agencies particular importance schering plough regulation fda european medicines agency emea ministry health labor welfare mhlw japan us fda jurisdiction scheringploughs businesses administers requirements covering testing approval safety effectiveness manufacturing labeling marketing scheringploughs products fda also regulates conversion pharmaceuticals prescription otc status extent fda requirements andor reviews affects amount resources necessary develop new products bring market us scheringploughs activities outside us european union japan also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing scheringploughs products regulatory requirements vary country country whether fda mhlw emea approval obtained product approval product comparable regulatory authorities countries outside us japan european union case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country failure comply governmental regulations result delays release products delays approvals new products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions scheringplough subject pharmacovigilance reporting requirements many countries jurisdictions including us european union eu eu member states requirements differ jurisdiction jurisdiction include requirements reporting adverse events occur patient using particular drug order alert manufacturer drug governmental agency potential problems fda regulation ongoing basis fda regulates facilities procedures used manufacture pharmaceutical products us sale us products made facilities manufactured accordance current good manufacturing practices cgmps established fda fda periodically inspects scheringploughs facilities procedures evaluate compliance fda consent decree may scheringplough announced reached agreement fda consent decree resolve issues involving scheringploughs compliance cgmps certain manufacturing facilities new jersey puerto rico consent decree requires scheringplough complete number actions including comprehensive cgmp work plans scheringploughs manufacturing facilities new jersey puerto rico revalidation finished drug products bulk active pharmaceutical ingredients manufactured facilities table contents information payments made decree completion deadlines possible payments ramifications deadlines missed discussed detail note consent decree item financial statements supplementary data k pricing reimbursement regulation international markets scheringplough operates environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods cost control recent years various legislative proposals offered congress many state legislatures would effect major changes affected health care systems states passed legislation federal state legislative administrative proposals possible could include price patient reimbursement constraints medicines mandated discounts supplemental rebates expansion existing governmental programs new patient populations restrictions access certain products similar issues also arisen many countries outside us possible predict outcome initiatives effect operations cash flows reasonably estimated scheringplough predict net effect medicare prescription drug benefit markets sales new medicare drug benefit medicare part take effect january offer voluntary prescription drug coverage subsidized medicare million medicare beneficiaries competing private prescription drug plans pdps medicare advantage plans many scheringploughs leading drugs already covered medicare part b eg temodar integrilin intron medicare part b provides payment physician services include prescription drugs administered incident physicians services beginning medicare part b drugs reimbursed manner may limit scheringploughs ability offer large price concessions make large price increases drugs scheringplough drugs relatively small portion sales medicare population eg clarinex hepatitis c franchise scheringplough could experience expanded utilization vytorin zetia new drugs scheringploughs rd pipeline greater consequence scheringplough may legislations impact pricing rebates discounts regulation scheringplough also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission ftc department justice department health human services us scheringplough therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies information merck scheringplough cholesterol joint venture may company merck co inc merck entered two separate agreements jointly develop market us two cholesterol lowering drugs allergy asthma drug december cholesterol agreement expanded include countries world except japan general companies agreed collaborative activities agreements would operate virtual mode maximum degree possible relying respective infrastructures two companies agreements generally provide equal sharing development costs copromotion approved products company cholesterol agreements provide company merck jointly develop ezetimibe marketed zetia us asia ezetrol europe oncedaily monotherapy ii coadministration statin drug table contents iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor mercks cholesterolmodifying medicine combination medication ezetimibe simvastatin marketed vytorin us inegy many international countries zetia ezetrol ezetimibe vytorin inegy combination ezetimibesimvastatin approved use us launched several international markets company utilizes equity method accounting joint venture cholesterol agreements provide sharing net income loss based upon percentages vary product sales level country us market scheringplough receives greater share profits first zetia sales zetia sales companies share profits equally scheringploughs allocation joint venture income increased milestones earned either partners share joint ventures net income loss subject reduction partner fails perform specified minimum number physician details particular country partners agree annually minimum number physician details country partners bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico cholesterol agreements provide reimbursement partner physician details reimbursed amount equal partners physician details multiplied contractual fixed fee scheringplough reports receipt reimbursement part equity income cholesterol joint venture us gaap amount represent reimbursement specific incremental identifiable costs companys detailing cholesterol products markets addition reimbursement amount per physician detail reflective scheringploughs joint venture sales force effort scheringploughs sales forcerelated infrastructure costs per physician detail generally estimated higher costs joint venture partners contractually share portion manufacturing costs specifically identified promotion costs including direct consumer advertising direct identifiable pocket promotion agreed upon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally partners due virtual nature joint venture company incurs substantial costs selling general administrative costs reflected equity income cholesterol joint venture borne overall cost structure company costs reported respective line items statements consolidated operations cholesterol agreements provide jointly owned facilities products resulting collaboration manufactured facilities owned either merck company allergy asthma agreement provides development marketing oncedaily fixedcombination tablet containing claritin singulair singulair mercks oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merck schering plough respiratory joint venture reported results phase iii clinical trials fixedcombination tablet containing claritin singulair phase iii study demonstrate sufficient added benefits treatment seasonal allergic rhinitis claritin singulair combination tablet approval country remains clinical development raw materials raw materials essential scheringplough available adequate quantities number potential suppliers energy expected available scheringplough sufficient quantities meet operating requirements table contents seasonality certain companys products particularly allergy suncare categories seasonal nature seasonal patterns pronounced effect consolidated operations scheringplough environment date compliance federal state local laws regarding discharge materials environment protection environment material effect scheringploughs capital expenditures earnings competitive position available information scheringploughs ks qs ks amendments reports filed sec available free charge scheringploughs website soon reasonably practicable materials electronically filed sec scheringploughs address world wide web scheringploughcom since scheringplough began practice third quarter report available scheringploughs website within hours filing reports filed scheringplough sec may read copied secs public reference room fifth street nw washington dc information operation public reference room may obtained calling sec sec sec also maintains internet site wwwsecgov contains reports proxy information statements information regarding issuers file electronically sec item properties scheringploughs corporate headquarters located kenilworth new jersey principal research facilities located kenilworth union summit new jersey palo alto california elkhorn nebraska principal manufacturing facilities follows location product type kenilworth new jersey pharmaceuti cals consumer products union new jersey pharmaceuticals miami florida pharmaceuticals consumer products omaha nebraska animal health cleveland tennessee consumer products puerto rico pharmaceuticals argentina pharmaceuticals belgium pharmaceuticals consumer products canada pharmaceuticals consumer products france pharmaceuticals animal health germany animal health ireland pharmaceuticals consumer products animal health italy pharmaceuticals japan pharmaceuticals consumer products mexico pharmaceuticals consumer products singapore pharmaceuticals spain pharmaceuticals may scheringplough announced reached agreement fda enter consent decree resolve issues involving schering ploughs compliance cgmp certain manufacturing facilities new jersey puerto rico refer government regulation section within item k note consent decree item financial statements supplementary data k additional information regarding consent decree table contents aforementioned properties owned leased scheringplough properties generally well maintained insured good operating condition scheringploughs manufacturing facilities capacities considered appropriate meet scheringploughs needs item legal proceedings material pending legal proceedings ordinary routine litigation incidental business scheringplough corporation subsidiaries property subject disclosed patent matters described patents trademarks intellectual property rights part business k intellectual property protection critical scheringploughs ability successfully commercialize product innovations litigation regarding scheringploughs intellectual property rights always pending initiated third parties attempting abridge scheringploughs rights well scheringplough protecting rights patent matters described potential material effect company dr scholls freeze away patent july orasure technologies filed action us district court eastern district pennsylvania alleging patent infringement scheringplough healthcare products sale dr scholls freeze away wart removal product complaint seeks permanent injunction unspecified damages including treble damages freeze away product launched march net sales product totaled approximately million investigations massachusetts investigation us attorneys office district massachusetts investigating broad range companys sales marketing clinical trial practices programs along warrick pharmaceuticals warrick companys generic subsidiary scheringplough disclosed connection investigation may schering corporation wholly owned significant operating subsidiary scheringplough received letter boston target letter office advising schering corporation including subsidiaries divisions target federal criminal investigation respect four areas providing remuneration drug samples clinical trial grants items services value managed care organizations physicians others induce purchase schering pharmaceutical products sale misbranded unapproved drugs company understands mean drugs promoted indications approval us fda obtained socalled offlabel uses submitting false pharmaceutical pricing information government purposes calculating rebates required paid medicaid program failing include prices product manufactured sold private label arrangement managed care customer well prices free nominally priced goods provided customer induce purchase schering products document destruction obstruction justice relating governments investigation target defined department justice guidelines person prosecutor grand jury substantial evidence linking commission crime judgment prosecutor putative defendant us attorneys manual section company implemented certain changes sales marketing clinical trial practices continuing review practices ensure compliance relevant laws regulations company cooperating investigation table contents see information prior increases liabilities reserved financial statements including relation investigation litigation charges note special charges additional information reserves potential impacts outcome litigation background section note legal environmental regulatory matters item financial statements supplementary data k outcome investigation could include commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs discussed background section note legal environmental regulatory matters contained item financial statements supplemental data company previously recorded liability approximately million related investigation reasonably possible settlement investigation could involve amounts materially excess accrual could material adverse impact companys financial condition cash flows operations required us gaap since company reasonably estimate potential final resolution company recognized estimated minimum liability company predict timing resolution matters outcomes nitrodur investigation august company received civil investigative subpoena issued office inspector general us department health human services seeking documents concerning companys classification nitrodur medicaid rebate purposes companys use nominal pricing bundling product sales company cooperating investigation appears subpoena one number addressed pharmaceutical companies concerning inquiry issues relating payment government rebates consumer products matter us department justice antitrust division investigated whether companys consumer products division entered agreement another company lower commission rate consumer products broker department closed investigation letter dated november pricing matters awp investigations company continues respond investigations department health human services department justice certain states industry company practices regarding average wholesale price awp investigations include department justice review merits federal action filed private entity behalf us us district court southern district florida well investigation us attorneys office district massachusetts regarding inter alia whether awp set pharmaceutical companies certain drugs improperly exceeds average prices paid dispensers consequence results unlawful inflation certain government drug reimbursements based awp march company received subpoena massachusetts attorney generals office seeking documents concerning use awp pricing andor marketing practices company also responded subpoenas attorney general california concerning matters company cooperating investigations outcome investigations could include imposition substantial fines penalties injunctive administrative remedies prescription access litigation december prescription access litigation project pal bostonbased group formed litigate drug companies filed class action suit federal court massachusetts company september consolidated complaint filed court result coordination multidistrict litigation panel federal court awp cases throughout country consolidated complaint alleges company warrick pharmaceuticals warrick companys generic subsidiary conspired providers defraud consumers reporting fraudulently high awps prescription medications reimbursed medicare thirdparty payers complaint seeks declaratory judgment unspecified damages including treble damages included litigation described prior paragraph lawsuits allege company warrick reported inflated awps prescription pharmaceuticals thereby caused state federal entities table contents thirdparty payers make excess reimbursements providers actions also allege company warrick failed report accurate prices medicaid rebate program thereby underpaid rebates states cases filed state attorneys general also seek recover behalf citizens state entities located state excess payments result inflated awps actions began october brought state attorneys general private plaintiffs nonprofit organizations employee benefit funds allege violations federal state law including fraud antitrust racketeer influenced corrupt organizations act rico claims first quarter company warrick among five groups companies put accelerated discovery track proceeding addition warrick company defendants number lawsuits state courts actions generally brought states andor political subdivisions seek unspecified damages including treble punitive damages securities class action litigation february company stated press release fda conducting inspections companys manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices primarily relating production processes controls procedures next day february lawsuit filed us district court district new jersey company certain named officers alleging violations sections b securities exchange act rule b promulgated thereunder additional lawsuits tenor followed complaints consolidated one action us district court district new jersey lead plaintiff florida state board administration appointed court july october consolidated amended complaint filed alleging violations described purporting represent class shareholders purchased shares company stock may february complaint seeks compensatory damages behalf class companys motion dismiss consolidated amended complaint denied may october court certified shareholder class discovery ongoing addition lawsuits described two lawsuits filed us district court district new jersey two lawsuits filed new jersey state court company nominal defendant certain officers directors former director seeking damages behalf company including disgorgement trading profits made defendants allegedly obtained basis material nonpublic information complaints four lawsuits relate issues described companys february press release allege failure disclose material information breach fiduciary duty directors one federal court lawsuits also includes allegations related investigations us attorneys offices eastern district pennsylvania district massachusetts ftcs administrative proceeding company lawsuit state texas warrick companys generic subsidiary lawsuits shareholder derivative action purports assert claims behalf company demand made board directors decision made whether company pursue claims august plaintiffs new jersey state court shareholder derivative actions moved dismiss voluntarily complaints actions motions granted two shareholder derivative actions pending us district court district new jersey consolidated one action early stages january company received demand letter dated december law firm involved derivative actions described behalf shareholder also involved derivative actions demanding board directors bring claims behalf company based allegations substantially similar alleged derivative actions january board directors adopted board resolution establishing evaluation committee consisting three directors investigate review analyze facts circumstances surrounding allegations made demand letter consolidated amended derivative action complaint described reserving full board authority discretion exercise business judgment respect proper disposition demand committee engaged independent outside table contents counsel advise issued report findings investigation independent directors board late october report determined shareholder demand refused finding liability part officers directors november full board adopted recommendation evaluation committee company defendant number purported nationwide state class action lawsuits plaintiffs seek refund purchase price laxatives phenylpropanolaminecontaining coughcold remedies ppa products purchased pharmaceutical manufacturers codefendants lawsuits general plaintiffs claim would purchased would paid less products known certain defects medical risks attendant use litigation claims relating companys ppa products courts national class action suit several state class action suits denied certification dismissed suits similar application deny class certification new jersey remaining statewide class action suit involving company granted september approximately individual lawsuits relating laxative products ppa products recalled albuterolvancerilvancenase inhalers also pending company seeking recovery personal injuries death number lawsuits punitive damages claimed march company served putative class action complaint filed us district court new jersey alleging company richard jay kogan resigned chairman board november retired chief executive officer president director company april companys employee savings plan plan administrator breached fiduciary obligations certain participants plan may company served second putative class action complaint filed court allegations nearly identical complaint filed march october consolidated amended complaint filed names additional defendants seven current former directors corporate officers complaint seeks damages amount losses allegedly suffered plan court dismissed complaint june july plaintiffs filed notice appeal antitrust ftc matters kdur kdur scheringploughs longacting potassium chloride product supplement used cardiac patients scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle related generic versions kdur lederle upsher smith filed abbreviated new drug applications andas april ftc started administrative proceeding scheringplough upshersmith lederle complaint alleged anticompetitive effects settlements june administrative law judge overseeing case issued decision patent litigation settlements complied law respects dismissed claims company ftc staff appealed decision full commission december full commission issued opinion reversed decision ruled settlements violate antitrust laws full commission issued cease desist order imposing various injunctive restraints opinion filed march federal court appeals set aside commission ruling vacated cease desist order following commencement ftc administrative proceeding alleged class action suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits allege essentially facts claim violations federal state antitrust laws well state statutory andor common law causes action suits seek unspecified damages discovery ongoing table contents sec inquiries related litigation september lawsuit filed new jersey superior court union county richard jay kogan companys outside directors alleging breach fiduciary duty fraud deceit negligent misrepresentation relating alleged disclosures made meetings subject settlement sec enforcement proceedings regulation fd plaintiffs seek imposition constructive trust profits plaintiffs allege realized defendants unlawful acts plaintiffs seek compensatory damages company removed case federal court case remanded state court company filed motion dismiss pending administrative obligations disclosed notes consent decree legal environmental regulatory matters item financial statements supplementary data k scheringplough subject obligations consent decree fda corporate integrity agreement potential penalties failure comply obligations tax matters october irs auditors asserted company liable additional tax tax years based allegations two interest rate swaps unrelated party recharacterized loans affiliated companies april company received formal notice deficiency statutory notice irs asserting additional federal income tax due company received bills related matter irs september payment amount million income tax million interest made september company filed refund claims tax interest irs december company notified february refund claims denied company believes complied applicable rules regulations intends file suit refund full amount tax interest environmental matters discussed note legal environmental regulatory matters item financial statements supplementary data k superfund sites discussed environmental section note considered normal scheringploughs business matters false claims act complaint april company received notice false claims act complaint brought individual purporting act behalf us government approximately pharmaceutical companies us district court northern district texas complaint alleged pharmaceutical companies including scheringplough defrauded us made sales various federal governmental agencies drugs allegedly manufactured manner comply current good manufacturing practices court granted scheringploughs motion dismiss january emea pharmacovigilance matter pharmacovigilance inspections officials british french medicines agencies conducted request european medicines agency emea serious deficiencies reporting processes identified scheringplough continues work action plan rectify deficiencies provides regular updates emea company know action emea national authorities take response findings possible actions include inspections demands improvements reporting systems criminal sanctions company andor responsible individuals changes conditions marketing authorizations companys products biopharma contract dispute biopharma srl filed claim civil court rome july docket th chamber certain scheringplough subsidiaries matter relates table contents certain contracts dated november distribution supply agreements biopharma scheringplough subsidiary distribution scheringplough generic products manufactured biopharma hospitals pharmacists france july letter agreement among biopharma scheringplough subsidiary medipha sante sa appointing medipha distribute products france biopharma alleges scheringplough fulfill duties contracts additional information legal proceedings additional information legal proceedings including important financial information found litigation charges discussion note special charges note legal environmental regulatory matters contained item financial statements supplementary data item managements discussion analysis financial condition results operations k item submission matters vote security holders applicable executive officers registrant following information regarding executive officers included herein accordance part iii item corporate officers also listed officers elected serve one year successors shall duly elected name current position business experience ge robert j bertolini present position executive vice president partner pricewaterhousecoopers chief financial officer richard bowles iii present position senior vice president vice president quality merck company global quality operations c ron cheeley present position senior vice president group vice president global compensation benefits pharmacia corporation global human resources carrie cox present position executive vice president president global executive vice president president global prescription business pharmacia pharmaceuticals corporation senior vice president head global business management pharmacia upjohn william j creelman present position vice president taxes senior tax counsel pfizer vice president tax us smithkline beecham douglas j gingerella present position vice president controller vice president corporate audits staff vice president corporate audits fred hassan present position chairman chief executive officer president chairman board chief executive officer pharmacia corporation chief executive officer pharmacia corporation chief executive officer pharmacia upjohn thomas h kelly present position vice president corporate business development vice president controller raul e kohan present position group head global specialty operations president animal health table contents name current position business experience ge joseph j larosa present position vice president legal affairs staff vice president secretary associate general counsel senior legal director legal director ian mcinnes present position senior vice president executive vice president supply chain senior vice president global global supply chain supply chain pharmacia corporation e kevin moore present position vice president treasurer daniel nichols present position senior vice president taxes cecil b pickett phd present position vice president president scheringplough research executive vice president discovery research scheringplough research institute institute anne renahan present position vice president corporate audits executive director controller eisai inc thomas j sabatino jr present position executive vice president general counsel senior vice president general counsel baxter international inc vice president general counsel baxter international inc brent saunders present position senior vice president partner pricewaterhousecoopers chief risk officer coventry health global compliance care business practices karl salnoske present position vice president chief ceo adaptive trade general manager ibm information officer susan ellen wolf present position corporate secretary various positions scheringploughs law department senior associate general attorney delta airlines counsel vice president officers defined rule af securities exchange act table contents part ii item market registrants common equity related stockholder matters common share dividends share price data approximate number holders record set forth item financial statements supplementary data k table provides information respect purchases company common shares fourth quarter issuer purchases equity securities tot al number max imum number shares purchased shares may part publicly yet purchased total number average price paid announced plans plans period shares purchased per share programs programs october hrough october na na november november na na december december na na total october december na na shares included table repurchased pursuant companys stock incentive program represent shares delivered company option holders payment exercise price tax withholding obligations connection stock options stock awards table contents item selected financial data million except per shar e figures perc entages operating results net sales lossincome income taxes net loss income net loss income available common shareholders diluted lossearnings per common share basic lossearnings per common share research development expenses depreciation amortization expenses financial position cash flows property net total assets longterm debt shareholders equity capital expenditures financial statistics net loss income percent net sales return average shareholders equity net book value per common share data cash dividends per common share cash dividends common shares cash dividends preferred shares average shares outstanding used calculating diluted loss earnings per common share average shares outstanding used calculating basic loss earnings per common share common shares outstanding yearend include special charges respectively see note special charges item financial statements supplementary data k additional information assumes conversion preferred shares approximately million common shares table contents item managements discussion analysis financial condition results operations executive summary overview company scheringplough company discovers develops manufactures markets medical therapies treatments enhance human health company also markets leading consumer brands overthecounter otc foot care sun care markets operates global animal health business researchbased pharmaceutical company scheringploughs core strategy invest substantial amounts funds scientific research goal creating important medical commercial value research development activities focus mechanisms treat serious diseases high rate failure inherent research result high risk funds invested research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase commercial phase may take decade highrisk nature research investments financial resources typically must come internal sources operations cash reserves equitytype capital two sources new products products acquired acquisition licensing arrangements products companys latestage research pipeline respect acquisitions licensing limited opportunities obtaining licensing critical latestage products limited opportunities typically require substantial amounts funding company competes opportunities companies often far greater financial resources company due present financial situation may challenging company acquire license critical latestage products positive material financial impact past three years company experienced number negative events strained continue strain companys financial resources negative events included limited following matters entered formal consent decree us food drug administration fda agreed revalidate manufacturing processes certain manufacturing sites us puerto rico significant increased spending associated manufacturing compliance efforts continue completion fda consent decree obligation addition company found necessary discontinue certain older profitable products outsource products switch claritin us beginning december prescription otc status switch coupled private label competition resulted much lower average unit selling price product ongoing intense competition companys exposure powerful retail purchasers also increased market shares sales levels certain company products fallen significantly experienced increased competition many products compete declining volatile markets investigations certain companys sales marketing practices us attorneys offices massachusetts pennsylvania company made payments totaling million us attorneys office eastern district pennsylvania settlement investigation massachusetts investigation continuing poses significant financial commercial risks company response matters beginning april company appointed new management team formulated begun implement six eightyear action agenda stabilize repair turn around company company intends avail foreign earnings repatriation provisions american jobs creation act act company intends repatriate billion unremitted foreign earnings reduced tax rate repatriation funds provide company greater financial stability table contents current state business past two years companys earnings cash flow declined significantly overriding cause loss marketing exclusivity two companys major pharmaceutical products claritin rebetol well increased competition hepatitis c market sales marketing costs increased due need reinvest functions launch new products well need stabilize market shares companys remaining pharmaceutical products many companys manufacturing sites operate well optimum production levels due sales declines reduction output related fda consent decree time overall costs operating manufacturing sites significantly increased due consent decree compliance activities company continues review carrying value assets indications impairment future events decisions may lead asset impairments andor related costs company continues pursue core strategy supporting marketed new products research development pipeline plans invest sales marketing scientific research historical levels however level investment sustainable without significant increase profits cash flow operations ability company generate profits significant operating cash flow directly predominantly dependent upon increasing profitability companys cholesterol franchise includes vytorin zetia much lesser extent growing sales profitability base pharmaceutical business products developing acquiring new products controlling expenses company generate significant operating cash flow ability invest sales marketing research efforts historical levels may negatively impacted zetia companys novel cholesterol absorption inhibitor vytorin combination zetia zocor mercks statin medication two products launched joint venture company merck cholesterolreduction market single largest pharmaceutical market world vytorin zetia well positioned market products compete well established cholesterol management products marketed companies financial resources much greater company financial commitment compete market shared merck profits sales vytorin zetia also shared merck management provide assurance profits nearterm sufficient company maintain core marketing research strategies sufficient level profit cash flow achieved company would need evaluate strategic alternatives regard examination strategic alternatives contracts merck vytorin zetia contract centocor inc remicade exhibits r u respectively companys contain provisions related change control defined contracts provisions could result aforementioned products acquired merck reverting back centocor inc regulatory environment company operates government regulatory agencies throughout world regulate companys discovery development manufacturing marketing efforts fda central regulator companys business since company working fda resolve issues involving companys compliance current good manufacturing practices cgmp certain manufacturing sites new jersey puerto rico company reached formal agreement fda enter consent decree terms consent decree company made payments totaling million agreed revalidate manufacturing processes sites manufacturing sites remained open throughout period however consent decree placed significant additional controls production release products sites including review thirdparty certification production activities thirdparty certifications cgmp improvement projects resulted higher costs well reduced output facilities addition company found necessary discontinue certain profitable older products companys research development operations also negatively impacted decree operations share common facilities manufacturing operations table contents us pricing companys pharmaceutical products subject competitive pressure managed care organizations seek price discounts also us company required provide statutorily defined rebates various government agencies order participate medicaid veterans health care program governmentfunded programs international markets company operates environment governmentmandated cost containment programs recently clinical trials postmarketing surveillance certain marketed drugs within industry raised safety concerns led recalls withdrawals adverse labeling marketed products addition situations raised concerns among prescribers patients relating safety efficacy pharmaceutical products general company continues maintain robust process monitoring adverse events related products around world company personnel regular open dialogue fda regulators review product labels materials regular basis new information becomes known july scheringplough corporation us department justice us attorneys office eastern district pennsylvania announced settlement related certain companys sales marketing practices investigation terms settlement subsidiary scheringplough corporation pled guilty single federal criminal charge concerning payment managed care customer addition settlement scheringplough corporation also entered fiveyear corporate integrity agreement cia failure comply cia result financial penalties settlement affect ability scheringplough corporation participate federal healthcare programs discussion operating results net sales consolidated net sales totaled billion decrease million percent compared consolidated net sales reflected primarily volume declines offset favorable foreign exchange rate impact percent consolidated net sales billion decreased billion percent versus reflecting primarily volume declines offset favorable foreign exchange rate impact percent table contents net sales years ended december follows incr ease dec rease llars illions prescription pharmaceuticals remicade clarinex aerius nasonex pegintron temodar integrilin claritin rxa intron rebetol subutex elocon caelyx pharmaceutical consumer health care otcb nm foot care sun care animal health consolidated net sales certain prior year amounts reclassified conform current year presentation n meaningful percentage amounts shown include international sales claritin rx b includes otc claritin respectively international net sales remicade treatment rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis million percent million due greater medical use expanded indications european markets sales remicade million million percent compared primarily europe due increased patient utilization global net sales clarinex marketed aerius many countries outside us treatment seasonal outdoor allergies yearround indoor allergies million essentially flat versus sales outside us increased percent million due market share gains continued conversion prescription claritin us sales decreased percent million due continued contraction us prescription antihistamine market following launch otc claritin branded nonbranded nonsedating antihistamines coupled market share declines global net sales clarinex million increase percent compared million reflecting continued conversion patients prescription claritin coupled launch clarinex several international markets global net sales nasonex nasal spray oncedaily corticosteroid nasal spray allergies rose percent million primarily due international sales growth favorable prior year trade inventory comparisons us tempered decline us market share sales nasonex decreased percent versus million due changes us trade inventory levels market share declines us table contents global net sales pegintron powder injection pegylated interferon product treating hepatitis c decreased percent million compared due ongoing market competition contracting market market share pegintron declining reflecting entrance competitors new products hepatitis c market sales pegintron decreased million percent million compared due primarily loss market share global net sales intron injection chronic hepatitis b c antiviral anticancer indications decreased percent million due primarily lower demand sales intron million decline percent due primarily loss market share global net sales rebetol capsules use combination intron pegintron treating hepatitis c decreased percent million due launch generic versions rebetol us april increased price competition outside us sales rebetol million decline percent billion due primarily loss market share resulting new branded competition global net sales temodar capsules treating certain types brain tumors increased million percent million due increased market penetration sales temodar million increase percent compared million due increased market penetration global net sales integrilin injection glycoprotein platelet aggregation inhibitor treatment patients acute coronary syndrome sold scheringplough primarily us increased million percent million due increased patient utilization sales integrilin million million respectively millennium pharmaceuticals inc millennium company copromotion agreement integrilin millennium notified company intends exercise right agreement assume responsibilities consumer service managed care contracting government reporting physical distribution integrilin result based final assumption agreement early fourth quarter company may required cease recording sales integrilin record share copromotion profits alliance revenue currently company anticipates change recording sales integrilin would impact earnings international net sales prescription claritin decreased percent million million due continued conversion clarinex global sales prescription claritin billion reflecting billion sales us prior conversion otc status international net sales subutex tablets treatment opiate addiction increased percent million due increased market penetration sales subutex million million subutex may vulnerable generic competition future global net sales elocon cream mediumpotency topical steroid increased percent million sales elocon million million generic competition expected affect sales product international sales caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma increased percent million reflecting adoption metastatic breast cancer indication patients increased cardiac risk sales caelyx increased percent versus million due increased patient utilization coupled launch metastatic breast cancer indication pharmaceutical net sales include large number lower sales volume prescription pharmaceutical products several products sold limited markets outside us many multiple source products longer protected patents products include treatments respiratory cardiovascular dermatological infectious oncological diseases table contents global net sales consumer health care products include otc foot care sun care products increased million percent billion net sales foot care products increased million percent due primarily strong performance dr scholls freeze away new wart remover product net sales sun care products increased million percent primarily due timing orders shipments sales otc claritin million decrease million percent due competition branded private label loratadine net sales consumer health care products increased million percent compared due primarily increased sales otc claritin following launch december global net sales animal health products increased percent million sales favorably impacted foreign exchange percent global net sales animal health products increased percent favorably impacted foreign exchange percent costs expenses equity income summary costs expenses equity income years ended december follows incr ease de crease llars illions cost sales net sales selling general administrative net sales research development net sales expense income net nm nm net sales special charges nm nm net sales equity income cholesterol joint venture nm nm n meaningful percentage certain prior year amounts reclassified conform current year presentation cost sales percentage net sales increased primarily due lower production volumes coupled increased spending related fda consent decree manufacturing compliance spending efforts upgrade companys global infrastructure absence european losec revenues change product sales mix including sales bayer licensed products contributed unfavorable comparison well companys base pharmaceutical business competing many declining volatile markets sales cost sales base business products direct impact gross margin cost sales percentage net sales increased due change product sales mix resulting loss us sales prescription claritin well lower production volumes increased spending companys cgmp compliance efforts substantially sales cholesterol products included companys net sales results operations joint venture reflected equity income impact companys gross operating margins selling general administrative expenses sga increased percent billion versus billion primarily due expansion sales field force higher employee related costs unfavorable impact foreign exchange partially offset lower promotional spending ratio sga net sales percent higher ratio percent sga expenses table contents decreased percent billion billion due lower pharmaceutical business marketing spending lower employee related costs ratio sga net sales percent higher ratio percent primarily due lower overall sales reported research development rd spending increased percent billion representing percent net sales includes million charge conjunction license toyama chemical company ltd toyama garenoxacin quinolone antibiotic currently development generally changes rd spending reflect timing companys funding internal research efforts research collaborations various partners discover develop steady flow innovative products increase expense income net primarily result higher net interest expense expense income net included million income related sale companys us marketing rights suboxone subutex sublingual tablets treatment opioid dependence special charges components special charges follows dollars million litigation charges employee termination costs asset impairment related charges litigation charges litigation reserves increased million million respectively primarily result investigations companys sales marketing practices employee termination costs august company announced global workforce reduction initiative first phase initiative voluntary early retirement program verp us program eligible employees us december elect early retirement receive enhanced retirement benefit approximately employees elected retire program approximately employees retired yearend approximately employees staggered retirement dates total cost program approximately million comprised increased pension costs million increased postretirement health care costs million vacation payments million costs related accelerated vesting stock grants million employees staggered retirement dates amounts recognized charge employees remaining service periods amounts recognized program million million respectively amount expected recognized million termination costs associated verp totaled million million respectively asset impairment related charges company recorded asset impairment related charges million million respectively charge relates primarily shutdown small european researchanddevelopment facility table contents asset impairment related charges related closure manufacturing facility united kingdom writedown production equipment related products longer produced manufacturing site operating fda consent decree writedown drug license sun care trade name expected cash flows support carrying value summary selected special charges following summarizes activity accounts related employee termination costs asset impairment related charges empl oyee asset imp airment termination related costs charges dollars millions special charges incurred impairment writedowns credit retirement benefit plan liability disbursements special charges liability balance december special charges incurred impairment writedowns credit retirement benefit plan liability disbursements special charges liability balance december equity income cholesterol joint venture global cholesterol franchise sales include sales made company cholesterol joint venture merck vytorin zetia totaled billion million respectively vytorin approved countries launched several countries including us july zetia approved countries launched us international markets since november company utilizes equity method accounting joint venture sharing net income based upon percentages vary product sales level country scheringploughs allocation joint venture income increased milestones earned partners bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico joint venture reimburses partner predefined amount physician details set annual basis scheringplough reports receipt reimbursement part equity income us gaap amount represent reimbursement specific incremental identifiable costs companys detailing cholesterol products markets addition reimbursement amount per physician detail reflective scheringploughs joint venture sales force effort scheringploughs sales forcerelated infrastructure costs per physician detail generally estimated higher costs joint venture partners contractually share portion manufacturing costs specifically identified promotion costs including directto consumer advertising direct identifiable outofpocket promotion agreedupon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally partners equity income cholesterol joint venture defined totaled million million respectively table contents company recognized milestones merck million million respectively relating approval ezetimibesimvastatin mexico certain european approvals zetia amounts included equity income certain conditions specified merck agreements merck could pay additional milestones company totaling million noted company incurs substantial costs selling costs reflected equity income cholesterol joint venture borne entirely company prior venture research development phase companys share research development expense million reported research development statements consolidated operations research development costs related joint venture included equity income provision income taxes tax expense million million million respectively tax provision includes charge approximately million tax charge million less million foreign tax credits related intended repatriation previously unremitted foreign earnings american jobs creation act act million foreign state taxes valuation allowance approximately million provided certain deferred tax assets resulting changes company tax planning strategies triggered opportunity take full advantage act see discussion overall impacts act company tax provision also includes us net operating loss us nol carryback benefit approximately million net loss income net loss million versus loss million net income billion net loss includes tax expense million primarily intended repatriation unremitted foreign earnings valuation reserve net deferred tax assets us net loss also reflects higher selling general administrative expenses associated buildup us sales force vytorin launch addition sales representatives result bayer licensing agreement well pretax special charges million described results also include pretax research development charge million license garenoxacin toyama chemical company ltd net loss includes special charges million described net income includes special charges million increase litigation reserves net loss available common shareholders net loss available common shareholders includes deduction preferred stock dividends million related issuance mandatory convertible preferred stock august impact american jobs creation act american jobs creation act act enacted law october one provision act effectively reduces tax rate qualifying repatriation funds held foreignbased subsidiaries percent normally repatriations would taxed rate percent qualify reduced tax rate funds must repatriated oneyear period fund qualifying expenditures us amount funds repatriated reduced tax rate limited amount unremitted foreign earnings reported companys annual report table contents company intends repatriate approximately billion act maximum amount funds qualifying reduced tax rate repatriation funds trigger us income tax payment approximately million net available tax credits financial reporting purposes tax payment recognized expense repatriating funds act benefit company following ways discussed detail liquidity financial resources section companys us operations incur significant negative cash flow expected repatriations made act provide company greater financial stability ability fund us cash needs intermediate term disclosed prior k q filings company intended fund future us cash flow deficits repatriating funds amounts us nols strategy would minimized taxes repatriations funds would also utilized us nols potential benefit able carry forward us nols reduce us taxable income future act qualifying repatriations reduce us tax losses result act company cash necessary fund us cash needs well maintaining potential benefit able carry forward us nols reduce us taxable income future potential future benefit could significant dependent company achieving profitability us us gaap companies must review provide valuation allowance deferred tax assets may future benefit company generally established valuation reserve net deferred tax assets fourth quarter due changes tax planning strategies triggered opportunity take full advantage act december company approximately billion us nols tax purposes available offset future us taxable income company general recorded valuation allowance net deferred tax assets us company expects additional us nols generated congress legislate certain technical corrections related act companys us nols could reduced approximately million stated company intends repatriate approximately billion december companys foreignbased subsidiaries held cash shortterm investments totaling approximately billion amount excludes billion cash foreignbased subsidiaries receive counterparty upon termination interest rate swap arrangement company terminate additionally foreignbased subsidiaries expected generate substantial cash flow available fund planned repatriation liquidity financial resources discussion cash flow operating activities used million cash amount includes receipt million us tax refund related carryback us nols payment million us government tax deficiency relating certain transactions entered payment million settlement agreement us attorneys office eastern district pennsylvania operating activities provided approximately million cash amount includes cash flow benefit reduction accounts receivable following end sales claritin prescription product us amount also includes million payment relating fda consent decree operating activities worldwide basis generated insufficient cash fund capital expenditures dividends cash flow deficit particularly pronounced disaggregated geographic basis foreign operations generate cash excess local cash needs however us operations table contents cash needs well excess cash generated us us operations must fund dividend payments vast majority research development costs us capital expenditures years prior overall us cash needs funded primarily operations following loss marketing exclusivity claritin december us profits cash generation declined materially cash requirements us including operating cash needs capital expenditures litigation tax charges dividends common preferred shares approximated billion company borrowed funds issued equity securities discussed finance us operations continued accumulate cash foreignbased subsidiaries management expects dividends capital expenditures worldwide basis exceed cash generated operating activities us operations continue generate negative cash flow payments regarding litigation investigations could increase cash needs management expects fund overall us cash flow deficit using cash investments currently held foreign subsidiaries american jobs creation act discussed provide company greater financial stability ability fund us cash needs intermediate term total cash cash equivalents shortterm investments less total debt approximately billion december company anticipates amount decline remain positive august company issued mandatory convertible preferred stock see note shareholders equity consolidated financial statements received net proceeds billion deducting commissions discounts underwriting expenses proceeds used reduce shortterm commercial paper borrowings pay settlement amounts litigation costs fund operating expenses shareholder dividends capital expenditures preferred stock issued companys billion shelf registration december million remains registered unissued shelf registration borrowings credit facilities november company issued billion aggregate principal amount senior unsecured notes due billion aggregate principal amount senior unsecured notes due proceeds offering billion used general corporate purposes including repaying commercial paper outstanding us upon issuance notes rated moodys investors service moodys credit watch negative implications standard poors sp interest rates payable notes subject adjustment rating assigned notes either moodys sp downgraded respectively interest rate payable series notes would increase see note shortterm borrowings longterm debt commitments consolidated financial statements additional information july moodys lowered rating notes baa accordingly interest payable note increased basis points effective december therefore december interest rate payable notes due increased interest rate payable notes due increased adjustment interest rate payable notes increase companys interest expense approximately million annually company two revolving credit facilities totaling billion facilities syndicate major financial institutions recently negotiated facility may billion fiveyear credit facility facility matures may requires company maintain total debt total capital ratio percent second credit facility provides million line credit maturity date may requires company maintain total debt total capital ratio percent time company rated baa moodys bbb sp facilities available general corporate purposes considered support companys commercial paper borrowings facilities require compensating balances however nominal commitment fee paid december funds drawn either facilities table contents december shortterm borrowings totaled billion approximately percent outstanding commercial paper commercial paper ratings discussed significantly affected companys ability issue rollover outstanding commercial paper borrowings time however company believes ability commercial paper issuers company one shortterm credit ratings p moodys sp andor f fitch ratings fitch issue rollover outstanding commercial paper times less companies higher shortterm credit ratings addition total amount commercial paper capacity available issuers typically less higherrated companies company maintains sizable lines credit commercial banks well cash shortterm investments held foreignbased subsidiaries serve alternative sources liquidity support commercial paper program credit ratings february sp downgraded companys senior unsecured debt ratings time sp also lowered companys short term corporate credit commercial paper rating companys sp rating outlook remains negative may shelf registration amended allowed company issue billion various debt equity securities declared effective sec march sp assigned shelf registration preliminary rating senior unsecured debt preliminary subordinated debt rating bbb september million remains registered unissued shelf registration april moodys placed companys senior unsecured credit rating watchlist possible downgrade based upon concerns related market share declines litigation risks high degree reliance success vytorin july moodys lowered companys senior unsecured credit rating baa lowered companys senior unsecured shelf registration rating pa pbaa lowered companys subordinated shelf registration rating pbaa pbaa lowered companys cumulative noncumulative preferred stock shelf registration rating pbaa pbaa confirmed companys p commercial paper rating removed company watchlist moodys rating outlook company negative see borrowings credit facilities section discussion impact moodys rating downgrade interest rates payable companys long term debt november fitch downgraded companys senior unsecured bank loan ratings commercial paper rating f f companys rating outlook remained negative announcing downgrade fitch noted sales decline companys leading product franchise time intron franchise greater anticipated concerned total company growth reliant performance two key growth drivers zetia remicade near term august fitch affirmed companys asenior unsecured rating bank loan rating f commercial paper rating reiterated negative outlook companys credit rating could decline impact decline could reduce availability commercial paper borrowing would increase interest rate companys longterm debt discussed company believes repatriation funds american jobs creation act allow company fund us cash needs intermediate term financial arrangements containing credit rating downgrade triggers company interest rate swap arrangement effect counterparty bank subject credit rating triggers arrangement utilizes two long term interest rate swap contracts one foreignbased subsidiary company bank us subsidiary company bank two contracts equal offsetting terms covered master netting arrangement contract involving foreignbased subsidiary permits subsidiary prepay portion future obligation bank contract involving us subsidiary permits bank prepay portion future obligation us subsidiary interest paid prepaid balances parties table contents market rates prepayments totaling billion made contracts december arrangement originally provided event company failed maintain required minimum credit ratings counterparty may terminate transaction designating early termination date earlier months following date notice terminate sps moodys current credit ratings specified minimum date k counterparty given company notice terminate december company counterparty mutually agreed amend swap contracts company counterparty agreed phased termination arrangement including repayment prepaid amounts based agreed schedule scheduled terminations associated repayment prepaid amounts begin later march end later january addition amended agreement month grace period previously applied event counterparty gives notice termination result companys failure maintain required minimum credit ratings extended january event counterparty gives company termination notice provision scheduled terminations associated payments continue according agreed repayment schedule time delivery termination notice january provisions original arrangement also allowed counterparty give month notice terminate transaction th anniversary transaction november companys credit ratings least moodys sp eliminated place company accepted new credit trigger provides counterparty may terminate transaction company fail maintain longterm us dollar denominated senior unsecured indebtedness rating least bbb sp baa moodys termination provision would later november days date company receives notice terminate company fail meet minimum credit requirement resulting early termination provision scheduled swap terminations associated payments continue termination date company may option accelerate scheduled terminations associated payments nominal fee february companys foreign based subsidiary us subsidiary gave notice counterparty terminate arrangement accordingly prepaid amounts repaid respective obligor company repay us obligation funds repatriated american jobs creation act see section entitled impact american jobs creation act table contents contractual obligations payments due period companys known contractual obligations december follows payme nts du e p erio less total year years years years dol lars millio ns longterm debt obligations operating lease obligations purchase obligations advertising contracts research contracts capital expenditure commitments purchase orders recorded longterm liabilities total longterm debt obligations include million aggregate principal amount percent senior unsecured notes due million aggregate principal amount percent senior unsecured notes due see note shortterm borrowings longterm debt commitments consolidated financial statements additional information research contracts include potential milestone payments made since payments contingent occurrence certain events table also excludes research contracts cancelable company without penalty open purchase orders consist cancelable noncancelable inventory expense items caption includes obligations based undiscounted amounts estimated payments certain companys pension plans hold qualified assets estimated payments companys deferred compensation plans environmental matters company responsibilities environmental cleanup various state local federal laws including comprehensive environmental response compensation liability act commonly known superfund environmental expenditures based information currently available anticipated material impact company see note legal environmental regulatory matters consolidated financial statements additional information additional factors influencing operations us many companys pharmaceutical products subject increasingly competitive pricing managed care groups institutions government agencies groups seek price discounts international markets company operates environment governmentmandated costcontainment programs us market company pharmaceutical manufacturers required provide statutorily defined rebates various government agencies order participate medicaid veterans health care program governmentfunded programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods control costs since company unable predict final form timing future domestic international governmental health care initiatives including passage laws permitting importation pharmaceuticals us effect operations cash flows reasonably estimated table contents similarly effect operations cash flows decisions government entities managed care groups groups concerning formularies pharmaceutical reimbursement policies reasonably estimated company predict net effect medicare prescription drug benefit markets sales new medicare drug benefit medicare part take effect january offer voluntary prescription drug coverage subsidized medicare million medicare beneficiaries competing private prescription drug plans pdps medicare advantage plans many companys leading drugs already covered medicare part b eg temodar integrilin intron medicare part b provides payment physician services include prescription drugs administered incident physicians services beginning medicare part b drugs reimbursed manner may limit scheringploughs ability offer larger price concessions make large price increases drugs scheringplough drugs relatively small portion sales medicare population eg clarinex hepatitis c franchise company could experience expanded utilization vytorin zetia new drugs companys rd pipeline greater consequence company may legislations impact pricing rebates discounts significant portion net sales made major pharmaceutical health care products distributors major retail chains us consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler buying decisions factors market pharmaceutical products competitive companys operations may affected technological advances competitors industry consolidation patents granted competitors new products competitors new information clinical trials marketed products postmarketing surveillance generic competition companys products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products effect operations competitive factors patent disputes predicted company launched otc claritin us december also december competing otc loratadine product launched us privatelabel competition introduced company continues market clarinex desloratadine mg tablets treatment allergic rhinitis combines indication seasonal allergic rhinitis indication perennial allergic rhinitis well treatment chronic idiopathic urticaria hives unknown cause ability company capture maintain market share clarinex otc claritin us market depend number factors including additional entrants market allergy treatments clinical differentiation clarinex allergy treatments perception extent differentiation marketplace pricing differentials among otc claritin clarinex allergy treatments generic otc loratadine erosion rate otc claritin clarinex sales upon entry additional generic otc loratadine products whether one branded secondgeneration antihistamines switched prescription otc status clarinex experiencing intense competition prescription us allergy market prescription allergy market shrinking since otc switch claritin december additionally company implementing new marketing efforts address market share performance clarinex switch claritin otc status introduction competing otc loratadine resulted rapid sharp material decline claritin sales us companys results operations us sales prescription claritin products million percent companys consolidated global sales billion percent sales clarinex us abroad also materially adversely affected presence generic otc loratadine otc claritin light factors described management believes companys december introduction otc claritin well introduction competing otc loratadine product december additional entrants generic otc loratadine products market rapid sharp material adverse effect companys results operations table contents pegintron rebetol combination therapy hepatitis c contributed substantially sales lesser extent fourth quarter competing pegylated interferonbased combination product including brand ribavirin received regulatory approval major markets including us overall market share hepatitis c franchise declined sharply reflecting new market competition addition overall market value contracted management believes ability pegintron rebetol combination therapy maintain market share continue adversely affected competition hepatitis c marketplace generic forms ribavirin entered us market april october another generic ribavirin approved fda generic forms ribavirin compete companys rebetol ribavirin capsules us prior second half rebetol patents material companys business result introduction competitor pegylated interferon introduction generic ribavirin value important company product franchise severely diminished earnings cash flow materially negatively impacted october merck scheringplough pharmaceuticals announced fda approved zetia ezetimibe mg use either together statins treatment elevated cholesterol levels march company announced ezetimibe ezetrol marketed europe successfully completed european union eu mutual recognition procedure mrp completion mrp process eu member states well iceland norway grant national marketing authorization unified labeling ezetrol ezetrol launched many international markets merck scheringplough partnership also developed oncedaily tablet combining ezetimibe simvastatin zocor mercks cholesterolmodifying medicine product marketed vytorin us inegy many international markets ezetimibesimvastatin approved marketing several countries including germany april mexico march july merck scheringplough pharmaceuticals announced fda approved vytorin inegy completed mrp europe october september company announced entered agreement bayer intended enhance companies pharmaceutical resources agreement entered company primarily strategic purposes commencing october us puerto rico company began marketing selling distributing bayers primary care products including avelox cipro exclusive license agreement company pay bayer royalties excess percent products based sales unfavorable impact companys gross margin percentage also commencing october company assumed bayers responsibilities us commercialization activities related erectile dysfunction medicine levitra bayers copromotion agreement glaxosmithkline plc company reports share levitra results alliance revenue additionally terms agreement bayer supports promotion certain companys oncology products us key european markets defined period time japan upon regulatory approval bayer comarket companys cholesterol absorption inhibitor zetia arrangement include rights future cholesterol combination product zetia filed regulatory authorities japan fourth quarter agreement bayer potentially restricts company marketing products us would compete products strategic alliance result company expects may need sublicense rights garenoxacin quinolone antibacterial agent company licensed toyama company exploring options regard garenoxacin continue fulfill commitments toyama arrangement including taking product regulatory approval table contents uncertainties inherent government regulatory approval processes including among things delays approval new products formulations indications may also affect companys operations effect regulatory approval processes operations predicted company subject jurisdiction various national state local regulatory agencies therefore subject potential administrative actions particular importance fda us jurisdiction companys businesses administers requirements covering testing safety effectiveness approval manufacturing labeling marketing companys products time time agencies including fda may require company address various manufacturing advertising labeling regulatory issues noted relating companys current manufacturing issues failure comply governmental regulations result delays release products seizure recall products suspension revocation authority necessary production sale products discontinuance products fines civil criminal sanctions result could material adverse effect companys financial position results operations additional information regarding government regulation may affect future results provided part item business annual report additional information cautionary factors may affect future results provided caption cautionary factors may affect future results cautionary statements private securities litigation reform act managements discussion analysis operations financial condition included note consent decree consolidated financial statements may company announced reached agreement fda consent decree resolve issues involving companys compliance current good manufacturing practices certain manufacturing facilities new jersey puerto rico us district court district new jersey approved entered consent decree may terms consent decree company agreed pay total million us government two equal installments million first installment paid may second installment paid may previously reported company accrued million provision consent decree fourth quarter consent decree requires company complete number actions event certain actions agreed upon consent decree satisfactorily completed time fda may assess payments deadline missed consent decree required company develop submit fdas concurrence comprehensive cgmp work plans companys manufacturing facilities new jersey puerto rico covered decree company received fda concurrence proposed cgmp work plans may cgmp work plans contain number significant steps whose timely satisfactory completion subject payments per business day deadline missed payments may exceed million million years payments subject overall cap million connection discussions fda regarding companys cgmp work plans pursuant terms decree company fda entered letter agreement dated april letter agreement company fda agreed extend six months time period company may incur payments described respect certain significant steps whose due dates december letter agreement increase yearly overall caps payments described addition decree requires company complete programs revalidation finished drug products bulk active pharmaceutical ingredients manufactured covered manufacturing facilities company required consent decree complete revalidation programs bulk active pharmaceutical ingredients september finished drugs december general timely satisfactory completions revalidations subject payments per business day deadline missed subject caps described however product scheduled revalidation certified validated last date validation schedule fda may assess payment percent net domestic sales uncertified product table contents validation certified payment would subject caps described general product scheduled revalidation consent decree certified within six months scheduled date company must cease production product certification obtained completion significant steps work plans completion revalidation programs subject thirdparty expert certification well fdas acceptance certification consent decree provides company believes may able meet deadline company right upon showing good cause request extensions deadlines connection cgmp work plans revalidation programs however guarantee fda grant requests although company believes made significant progress meeting obligations consent decree possible company may fail complete significant step revalidation prescribed deadline thirdparty expert may certify completion significant step revalidation fda may disagree experts certification significant step revalidation case possible fda may assess payments described company would expense payments assessed decree incurred addition failure meet terms consent decree could result delays approval new products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions april company received notice false claims act complaint brought individual purporting act behalf us government approximately pharmaceutical companies us district court northern district texas complaint alleges pharmaceutical companies including company defrauded us made sales various federal governmental agencies drugs allegedly manufactured manner comply current good manufacturing practices company defendants filed motion dismiss second amended complaint action april company subject pharmacovigilance reporting requirements many countries jurisdictions including us european union eu eu member states requirements differ jurisdiction jurisdiction include requirements reporting adverse events occur patient using particular drug order alert manufacturer drug governmental agency potential problems pharmacovigilance inspections officials british french medicines agencies conducted request european agency evaluation medicinal products emea serious deficiencies reporting processes identified company taking urgent actions rectify deficiencies quickly possible company know action emea national authorities take response findings possible actions include inspections demands improvements reporting systems criminal sanctions company andor responsible individuals changes conditions marketing authorizations companys products company sells numerous upper respiratory products contain pseudoephedrine pse fdaapproved ingredient relief nasal congestion companys annual sales upper respiratory products contain pse totaled approximately million approximately million products include claritind products well drixoral coricidin chlortrimeton products company understands pse used illicit manufacture methamphetamine dangerous addictive drug february states canada enacted regulations concerning sale pse including limiting amount products purchased one time requiring products located behind pharmacists counter stated goal deterring illicitillegal manufacture methamphetamine additional eight states enacted limits quantity pse person possess date regulations material impact companys operations financial results table contents described specifically note legal environmental regulatory matters consolidated financial statements pricing sales marketing programs arrangements related business practices company participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities entities include department justice us attorneys offices office inspector general department health human services fda federal trade commission ftc various state attorneys general offices many health care laws certain governmental entities operate including federal state antikickback statutes statutory common law false claims laws construed broadly courts permit government entities exercise significant discretion event governmental entities believes wrongdoing occurred one could institute civil criminal proceedings instituted resolved unfavorably could subject company substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs company also predict whether investigations affect marketing practices sales result could material adverse impact company financial condition cash flows results operations impact recently issued accounting standards november fasb issued statement financial accounting standard sfas inventory costs sfas requires abnormal spoilage expensed period incurred opposed inventoried amortized income inventory usage fixed production facility overhead costs allocated normal production level facility sfas effective inventory costs incurred annual periods beginning june company anticipate material impact implementation accounting standard december fasb issued sfas r revised share based payment statement r requires companies recognize compensation expense amount equal fair value sharebased payments granted employees companies required implement sfas july recognizing compensation sharebased grants made july unvested portion sharebased grants made prior july restatement previously issued statements allowed required company currently evaluating various implementation options available related financial impacts sfas r critical accounting policies following accounting policies considered significant changes certain judgments assumptions inherent policies could affect companys financial statements revenue recognition rebates discounts returns provision income taxes impairment intangible assets property accounting legal regulatory matters revenue recognition companys pharmaceutical products sold direct purchasers eg wholesalers retailers certain health maintenance organizations price discounts rebates sales paid federal state agencies well indirect purchasers market participants eg managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers table contents company recognizes revenue title risk loss pass purchaser reliable estimates following determined commercial discount rebate arrangements ii rebate obligations certain federal state governmental programs iii sales returns normal course business recognizing revenue company estimates records applicable commercial governmental discounts rebates well sales returns expected granted made products sold period amounts deducted sales period estimates recorded prior periods reevaluated part process reliable estimates items made company defers recognition revenue revenue recognition new products based specific facts circumstances including estimated acceptance rates established products similar marketing characteristics absent ability make reliable estimates rebates discounts returns company would defer revenue recognition product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates estimated based sales terms historical experience trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information data information provided purchasers obtained third parties subject inherent limitations accuracy validity sales returns generally estimated recorded based historical sales returns information analysis recent wholesale purchase information consideration stocking levels wholesalers forecasted demand amounts products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part formulation accruals company entered agreements major us pharmaceutical wholesalers agreements deal number commercial issues product returns timing payment processing chargebacks quantity inventory held wholesalers respect quantity inventory held wholesalers agreements provide financial disincentive wholesalers acquire quantities product excess necessary meet current patient demand use monitoring noted agreements company expects avoid situations companys shipments product reflective current demand rebates discounts returns rebate accruals federal state governmental programs million december million december commercial discounts rebate accruals million december million december respectively rebate accruals established period related revenue recognized resulting reduction sales establishment liability included accrued liabilities case governmental rebate programs companys payments involve interpretations relevant statutes regulations interpretations subject challenges changes interpretive guidance governmental authorities result challenge change could affect whether estimated governmental rebate amounts ultimately sufficient satisfy companys obligations additional information governmental inquiries focused part calculation rebates contained note legal environmental regulatory matters consolidated financial statements addition possible result governmental challenges changes interpretive guidance actual rebates could materially exceed amounts accrued table contents following summarizes activity accounts related accrued rebates sales returns discounts year en ded december dol lars millions accrued rebates returns discounts beginning period provision rebates payments provision returns returns provision discounts discounts granted accrued rebates returns discounts end period management makes estimates uses assumptions recording accruals actual amounts paid current period consistent previously estimated provision income taxes december taxes provided approximately billion undistributed earnings foreign subsidiaries considering impact american jobs creation act certain assets associated earnings repatriated us additional tax provisions may necessary tax contingencies recorded address potential exposures involving tax positions taken could challenged taxing authorities potential exposures result varying application statutes rules regulations interpretations including intercompany terms crossborder agreements affiliates management believes intercompany terms based sound economic facts circumstances utilization cash held foreign subsidiaries investment us property companys estimate accrual tax contingencies contains assumptions based past experiences judgments potential actions taxing jurisdictions reasonably possible ultimate resolution tax matters may materially greater less amounts accrued company records tax valuation allowance reduce deferred tax assets amount likely realized company considered ongoing prudent feasible tax planning strategies assessing need valuation allowance event company determine would able realize portion net deferred tax assets adjustment deferred tax asset would increase income period determination would made likewise company subsequently determine would able realize portion net deferred tax asset future adjustment deferred tax asset would charged income period determination made impairment intangible assets property intangible assets representing capitalized costs purchased goodwill patents licenses forms intellectual property totaled million december annual amortization expense next five years estimated approximately million per year based intangible assets recorded december value assets subject continuing scientific medical table contents marketplace uncertainty example marketed pharmaceutical product withdrawn market safety reasons marketing product could occur pronounced warnings amounts capitalized product may need reduced due impairment events giving rise impairment inherent risk pharmaceutical industry predicted management regularly reviews intangible assets possible impairment companys manufacturing sites operate well optimum levels due sales declines reduction output related fda consent decree time overall costs operating manufacturing sites increased due consent decree compliance activities impact material increase manufacturing costs company continues review carrying value assets indications impairment future events decisions may lead asset impairments andor related costs accounting legal regulatory matters management judgments estimates also required accounting legal regulatory matters particular company recognized estimated minimum liabilities connection certain government investigations sales marketing activities ultimate resolution matter could involve amounts materially excess amounts accrued could material adverse impact companys financial condition cash flows operations see note legal environmental regulatory matters consolidated financial statements market risk disclosure company exposed market risk primarily changes foreign currency exchange rates lesser extent interest rates equity prices following describes nature risks foreign currency exchange risk company subsidiaries countries sales outside us accounted approximately percent global sales virtually sales denominated currencies local country companys reported profits cash flows exposed changing exchange rates date management deemed cost effective engage formulabased program hedging profits cash flows foreign operations using derivative financial instruments companys foreign subsidiaries purchase significant quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provides level protection adverse changes exchange rates risk adverse exchange rate change also mitigated fact companys foreign operations widespread addition point time companys foreign subsidiaries hold financial assets liabilities denominated currencies us dollars financial assets liabilities consist primarily shortterm thirdparty intercompany receivables payables changes exchange rates affect financial assets liabilities gains losses arise translation affect net income occasion company used derivatives hedge specific shortterm risk situations involving foreign currency exposures however derivative transactions material interest rate equity price risk financial assets exposed changes interest rates andor equity prices debt equity securities held nonqualified trusts employee benefits assets totaled million december due longterm nature liabilities trust assets fund companys exposure market risk deemed low financial obligations exposed variability interest expense longterm shortterm borrowings company maintains cash cash equivalent portfolio excess amount borrowings table contents accordingly company mitigated exposure changes interest rates relating financial obligations company longterm debt outstanding percent decrease interest rates would change fair value debt million however company expect refund debt disclosure notice cautionary factors may affect future results cautionary statements private securities litigation reform act managements discussion analysis financial condition results operations sections report written reports oral statements made time time company may contain forwardlooking statements within meaning securities litigation reform act forwardlooking statements relate expectations forecasts future events use words anticipate believe could estimate expect forecast project intend plan potential words terms similar meaning connection discussion potential future events circumstances future operating financial performance also identify forwardlooking statements fact relate strictly historical current facts particular forwardlooking statements include statements relating future actions ability access capital markets prospective products status product approvals future performance results current anticipated products sales efforts development programs estimates rebates discounts returns expenses programs reduce expenses cost savings reductions work force outcome contingencies litigation investigations growth strategy financial results forwardlooking statements publications may turn wrong actual results may vary materially guarantees scheringploughs financial operational performance performance scheringplough stock scheringplough assume obligation update forwardlooking statement many factors could cause actual results differ scheringploughs forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known although possible predict identify factors may include following significant portion net sales made major pharmaceutical health care products distributors major retail chains us consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler buying decisions factors competitive factors including technological advances attained competitors patents granted competitors new products competitors coming market new indications competitive products new existing generic prescription andor otc products compete products schering plough merck scheringplough pharmaceuticals joint venture competition otc statins like one approved use uk impact cholesterol reduction market yet known increased pricing pressure us abroad managed care organizations institutions government agencies programs us among developments consolidation among customers may increase pricing pressures may result various customers greater influence prescription decisions formulary decisions policies potential impact medicare prescription drug improvement modernization act possible us legislation regulatory action affecting among things pharmaceutical pricing reimbursement including medicaid medicare involuntary approval prescription medicines overthe counter use health care reform initiatives drug importation table contents legislation legislation regulations markets outside us affecting product pricing reimbursement access laws regulations relating trade antitrust monetary fiscal policies taxes price controls possible nationalization patent positions highly uncertain patent disputes unusual adverse result patent dispute preclude commercialization products negatively impact sales existing products result injunctive relief payment financial remedies uncertainties fda approval process regulatory approval review processes countries including without limitation delays approval new products failure meet current good manufacturing practices established fda governmental authorities result delays approval products release products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions resolution manufacturing issues fda discussed scheringploughs ks qs ks subject substantial risks uncertainties risks uncertainties including timing scope duration resolution manufacturing issues depend ability schering plough assure fda quality reliability manufacturing systems controls extent remedial prospective obligations undertaken scheringplough difficulties product development pharmaceutical product development highly uncertain products appear promising development may fail reach market numerous reasons may found ineffective harmful side effects clinical preclinical testing may fail receive necessary regulatory approvals may turn economically feasible manufacturing costs factors may precluded commercialization proprietary rights others postmarketing issues product approved marketed clinical trials marketed products postmarketing surveillance may raise efficacy safety concerns whether scientifically justified new information could lead recalls withdrawals adverse labeling marketed products may negatively impact sales concerns prescribers patients relating safety efficacy scheringplough products companies products pharmaceutical products generally may also negatively impact sales major products claritin clarinex intron pegintron rebetol capsules remicade temodar nasonex accounted material portion scheringploughs revenues major product become subject problem loss patent protection otc availability companys product competitive product disclosed claritin current potential otc competition previously unknown side effects new effective treatment introduced generic availability competitive products product discontinued reason impact revenues could significant also information important new products zetia vytorin important products pipeline may impact future revenues sales vytorin may negatively impact sales zetia unfavorable outcomes government local federal domestic international investigations litigation product pricing product liability claims litigation environmental concerns could preclude commercialization products negatively affect profitability existing products materially adversely impact scheringploughs financial condition results operations contain conditions impact business operations exclusion government reimbursement programs economic factors scheringplough control including changes inflation interest rates foreign currency exchange rates table contents instability disruption destruction significant geographic region due location manufacturing facilities distribution facilities customers regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease changes tax laws including changes related taxation foreign earnings changes accounting auditing standards promulgated american institute certified public accountants financial accounting standards board sec public company accounting oversight board would require significant change scheringploughs accounting practices details discussion risks uncertainties see scheringploughs past future sec reports filings item quantitative qualitative disclosures market risk see market risk disclosures set forth item managements discussion analysis financial condition results operation table contents item financial statements supplementary data index financial statements statements consolidated operations years ended december statements consolidated cash flows years ended december consolidated balance sheets december statements consolidated shareholders equity years ended december notes consolidated financial statements report independent registered public accounting firm table contents scheringplough corporation subsidiaries statements consolidated operations ears e nded ecemb er amounts millions except per share figures net sales cost sales selling general administrative research development expense income net special charges equity income cholesterol joint venture lossincome income taxes income tax expense net lossincome preferred stock dividends net lossincome available common shareholders diluted lossearnings per common share basic lossearnings per common share accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated cash flows f th e ye ars e nded december amounts millions operating activities net lossincome adjustments reconcile net lossincome net cash used provided operating activities tax refund us loss carryback payments additional us tax special charges depreciation amortization changes assets liabilities accounts receivable inventories prepaid expenses assets accounts payable liabilities income taxes payable net cash used provided operating activities investing activities capital expenditures dispositions property equipment proceeds transfer license purchases investments reduction investments net net cash used investing activities financing activities cash dividends paid common shareholders cash dividends paid preferred shareholders proceeds preferred stock issuance net net change shortterm borrowings issuance longterm debt reductions longterm debt net net cash provided used financing activities effect exchange rates cash cash equivalents net increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries consolidated balance sheets decem ber amounts millions except per share figures assets current assets cash cash equivalents shortterm investments accounts receivable less allowances inventories deferred income taxes prepaid expenses current assets total current assets property cost land buildings improvements equipment construction progress total less accumulated depreciation property net goodwill intangible assets net assets total assets liabilities shareholders equity current liabilities accounts payable shortterm borrowings current portion longterm debt us foreign state income taxes accrued compensation accrued liabilities total current liabilities longterm liabilities longterm debt deferred income taxes longterm liabilities total longterm liabilities commitments contingent liabilities note shareholders equity mandatory convertible preferred shares par value issued per share face value common shares authorized shares par value issued paidin capital retained earnings accumulated comprehensive income total less treasury shares cost total shareholders equity total liabilities shareholders equity accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated shareholders equity accu mulated mandatory total convertible compre share preferred common paidin retained treasury hensive holders amounts millions shares shares capital earnings shares income equity balance january comprehensive income net income foreign currency translation minimum pension liability net tax realized gain reclassified income net tax total comprehensive income cash dividends common shares stock incentive plans balance december comprehensive income net loss foreign currency translation minimum pension liability net tax unrealized gain investments available sale net tax total comprehensive income loss cash dividends common shares stock incentive plans balance december comprehensive income net loss foreign currency translation minimum pension liability unrealized gain investments available sale total comprehensive income loss issuance preferred stock cash dividends common shares dividends preferred shares stock incentive plans balance december accompanying notes integral part consolidated financial statements table contents notes consolidated financial statements dollars millions except per share figures summary significant accounting policies principles consolidation consolidated financial statements include scheringplough corporation subsidiaries company intercompany balances transactions eliminated certain prior year amounts reclassified conform current year presentation use estimates preparation financial statements conformity generally accepted accounting principles requires management make estimates use assumptions affect certain reported amounts disclosures actual amounts may differ equity method accounting company accounts interest merck co inc merck joint venture using equity method accounting company significant influence operating financial policies accordingly companys share earnings merck joint venture included consolidated net lossincome revenue sales vytorin zetia recognized joint venture title risk loss passed customer equity income joint venture excludes profit arising transactions company joint venture time underlying profit realized joint venture transaction party company merck see note equity income cholesterol joint venture information regarding joint venture cash cash equivalents cash cash equivalents include operating cash highly liquid investments generally original maturities three months less included cash cash equivalents approximately restricted cash december respectively investments investments carried market value classified availableforsale inventories inventories valued lower cost market cost determined using lastin firstout lifo method substantial portion inventories located us cost inventories determined firstin firstout method fifo depreciation property equipment depreciation provided estimated useful lives properties generally use straightline method useful lives property follows asset category yea rs buildings building improvements equipment depreciation expense respectively company reviews carrying value property equipment indications impairment accordance statement financial accounting standard sfas accounting impairment disposal longlived assets foreign currency translation net assets companys foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation adjustment account included comprehensive income remaining foreign subsidiaries nonmonetary assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income table contents notes consolidated financial statements continued exchange gains losses arising translating intercompany balances longterm investment nature recorded foreign currency translation adjustment account exchange gains losses included income accumulated comprehensive income accumulated comprehensive income primarily consists accumulated foreign currency translation adjustment account unrealized gains losses securities classified available sale minimum pension liability adjustment components accumulated comprehensive income december accumulated foreign currency translation minimum pension liability net tax accumulated unrealized gains losses investments available sale net tax total gross unrealized pretax gains investments respectively unrealized losses immaterial revenue recognition companys pharmaceutical products sold direct purchasers eg wholesalers retailers certain health maintenance organizations price discounts rebates sales paid federal state agencies well indirect purchasers market participants eg managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers company recognizes revenue title risk loss pass purchaser reliable estimates following determined commercial discount rebate arrangements ii rebate obligations certain federal state governmental programs iii sales returns normal course business recognizing revenue company estimates records applicable commercial governmental discounts rebates well sales returns expected granted made products sold period amounts deducted sales period estimates recorded prior periods reevaluated part process reliable estimates items made company defers recognition revenue earnings per common share diluted loss per common share excludes effect shares issuable deferred stock units exercise stock options impact conversion mandatory convertible preferred shares including securities earnings per share calculation would antidilutive would result lower loss per share diluted loss per common share excludes effect shares issuable deferred stock units exercise stock options including securities would antidilutive diluted earnings per common share computed dividing income sum weightedaverage number common shares outstanding plus dilutive effect shares issuable deferred stock units exercise stock options periods presented basic earnings per common share computed dividing incomeloss available common shareholders weightedaverage number common shares outstanding table contents notes consolidated financial statements continued shares used calculate basic diluted earnings per common share reconciled follows year ended december shares million average shares outstanding basic earnings per share dilutive effect options deferred stock units average shares outstanding diluted earnings per share equivalent million million million common shares issuable companys stock incentive plans excluded computation diluted earnings per share december respectively effect would antidilutive addition million common shares issuable upon conversion companys mandatory convertible preferred stock excluded computation diluted loss per share effect would antidilutive goodwill intangible assets sfas goodwill intangible assets requires intangible assets acquired either individually group assets initially recognized measured based fair value intangible finite life amortized useful life intangible indefinite life including goodwill amortized company evaluates goodwill impairment using fair valuebased test goodwill determined impaired written estimated fair value companys goodwill primarily related animal health business components intangible assets net follows december gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net patents licenses trademarks total intangible assets intangible assets amortized straightline method respective useful lives residual value intangible assets estimated zero company recorded intangible assets related license copromotion agreements related levitra avelox amounts amortized effective useful lives agreements ranging seven years also net carrying amount patents licenses reduced approximately result bristolmyers squibbs reacquisition copromotion rights tequin us company paid patent licensing rights costs amortized approximately nine years amortization expense related intangible assets respectively intangible assets reviewed determine recoverability comparing carrying values expected undiscounted future cash flows events circumstances warrant review accounting stockbased compensation currently company accounts stock compensation arrangements using intrinsic value method stockbased employee compensation cost reflected net lossincome companys deferred stock units stock options granted plans exercise price equal market value underlying common stock date table contents notes consolidated financial statements continued grant companys deferred stock units stock options issued companys stock incentive plans see note december financial accounting standards board fasb issued sfas r revised share based payment statement r requires companies recognize compensation expense amount equal fair value sharebased payments granted employees companies required implement sfas july recognizing compensation sharebased grants made july unvested portion sharebased grants made prior july restatement previously issued statements allowed required company currently evaluating various implementation options related financial impacts available sfas r following table reconciles net lossincome available common shareholders basicdiluted lossearnings per common share reported pro forma net lossincome available common shareholders basicdiluted lossearnings per common share company expensed grantdate fair value stock options deferred stock units permitted sfas accounting stockbased compensation net lossincome available common shareholders reported add back expense included reported net income deferred stock units net tax deduct pro forma expense stock options deferred stock units charged net income net tax pro forma net lossincome available common shareholders using fair value method diluted lossearnings per common share diluted lossearnings per common share reported pro forma diluted lossearnings per common share using fair value method basic lossearnings per common share basic lossearnings per common share reported pro forma basic lossearnings per common share using fair value method weightedaverage fair value options granted respectively fair values estimated using blackscholes optionpricing model based following assumptions dividend yield volatility riskfree interest rate expected term options years table contents notes consolidated financial statements continued special charges components special charges year ended december follows litigation charges employee termination costs asset impairment related charges litigation charges litigation reserves increased respectively primarily result investigations companys sales marketing practices see note additional information employee termination costs august company announced global workforce reduction initiative first phase initiative voluntary early retirement program verp us program eligible employees us december elect early retirement receive enhanced retirement benefit approximately employees elected retire program approximately employees retired yearend approximately employees staggered retirement dates total cost program approximately comprised increased pension costs increased postretirement health care costs vacation payments costs related accelerated vesting stock grants employees staggered retirement dates amounts recognized charge employees remaining service periods delayed expense recognition follows guidance sfas accounting costs associated exit disposal activities amounts recognized relating program years ended december respectively termination costs associated verp totaled respectively asset impairment related charges asset impairment charges recognized accordance sfas goodwill intangible assets sfas accounting impairment disposal longlived assets year ended december company recognized asset impairment charges based discounted cash flows charges related primarily shutdown small european researchanddevelopment facility year ended december company recognized asset impairment charges related following asset impairment charges totaling recognized based discounted cash flow analysis related facilities equipment two companys manufacturing sites asset impairment charge based discounted cash flows recognized related intangible asset licensed cancer therapy drug sold countries outside us impairment charge related trade name companys highend sun care brand recognized based discounted cash flows table contents notes consolidated financial statements continued summary selected special charges following summarizes activity accounts related employee termination costs asset impairment charges ass et employee impairment termination related costs charges special charges incurred impairment writedowns credit retirement benefit plan liability disbursements special charges liability balance december special charges incurred impairment writedowns credit retirement benefit plan liability disbursements special charges liability balance december balance december represents distributions made yearend equity income cholesterol joint venture may company merck entered two separate agreements jointly develop market us two cholesterol lowering drugs allergyasthma drug december cholesterol agreement expanded include countries world except japan general companies agreed collaborative activities agreements would operate virtual mode maximum degree possible relying respective infrastructures two companies agreements generally provide equal sharing research development costs copromotion approved products company cholesterol agreements provide company merck jointly develop ezetimibe marketed zetia us asia ezetrol europe oncedaily monotherapy ii coadministration statin drug iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor mercks cholesterolmodifying medicine combination medication ezetimibesimvastatin marketed vytorin us inegy many international countries zetia ezetrol ezetimibe vytorin inegy combination ezetimibesimvastatin approved use us launched several international markets company utilizes equity method accounting joint venture cholesterol agreements provide sharing net incomeloss based upon percentages vary product sales level country us market scheringplough receives greater share profits first zetia sales zetia sales companies share profits equally scheringploughs allocation joint venture income increased milestones earned either partners share joint ventures net incomeloss subject reduction partner fails perform specified minimum number physician details particular country partners agree annually minimum number physician details country table contents notes consolidated financial statements continued partners bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico cholesterol agreements provide reimbursement partner physician details set annual basis reimbursed amount equal partners physician details multiplied contractual fixed fee scheringplough reports receipt reimbursement part equity income cholesterol joint venture us gaap amount represent reimbursement specific incremental identifiable costs companys detailing cholesterol products markets addition reimbursement amount per physician detail reflective scheringploughs joint venture sales force effort scheringploughs sales forcerelated infrastructure costs per physician detail generally estimated higher costs joint venture partners contractually share portion manufacturing costs specifically identified promotion costs including directto consumer advertising direct identifiable outofpocket promotion agreed upon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally partners following information provides summary components companys equity income cholesterol joint venture year ended december unau dited scheringploughs share net incomeloss including milestones respectively reimbursement scheringplough physician details elimination intercompany profit net total equity income cholesterol joint venture company earned milestones respectively relating approval ezetimibesimvastatin mexico certain european approvals ezetimibe certain conditions specified agreements merck could pay additional milestones company totaling equity income joint venture excludes profit arising transactions company joint venture time underlying profit realized joint venture transaction party company merck due virtual nature joint venture company incurs substantial costs selling general administrative costs reflected equity income cholesterol joint venture borne overall cost structure company costs reported respective line items statements consolidated operations cholesterol agreements provide jointly owned facilities products resulting joint venture manufactured facilities owned either merck company discussed company accounts merck scheringplough cholesterol partnership equity method accounting companys net sales include sales joint venture prior joint venture research development phase companys share research development expense reported research development statements consolidated operations allergyasthma agreement provides development marketing oncedaily fixedcombination tablet containing claritin singulair singulair mercks oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merck schering plough respiratory joint venture reported results phase iii clinical trials fixedcombination tablet table contents notes consolidated financial statements continued containing claritin singulair phase iii study demonstrate sufficient added benefits treatment seasonal allergic rhinitis claritin singulair combination tablet approval country remains clinical development expense income net components expense income net follows interest cost incurred less amount capitalized construction interest expense interest income foreign exchange gains losses net total net includes gain sale us marketing rights suboxone subutex cash paid interest net amounts capitalized respectively income taxes components consolidated lossincome income taxes years ended december follows united states foreign total lossincome income taxes components income tax expense benefit years ended december follows fede ral sta te fore ign tot al current deferred total current deferred total current deferred total table contents notes consolidated financial statements continued american jobs creation act act enacted october one provision act effectively reduces tax rate qualifying repatriation earnings held foreignbased subsidiaries percent normally repatriations would taxed rate percent fourth quarter company made decision intends repatriate approximately billion act maximum amount foreign earnings qualifying reduced rate intended repatriation earnings trigger us federal tax payment approximately tax charge less foreign tax credits state tax payment approximately amounts reflected current income tax expense prior act company provide deferred taxes undistributed earnings foreign subsidiaries company intended indefinitely reinvest undistributed earnings foreign subsidiaries company intent indefinitely reinvest undistributed earnings foreign subsidiaries repatriated act therefore provided deferred taxes approximately undistributed foreign earnings determining tax liability would arise earnings remitted practicable amount would depend number factors including amount earnings distributed whether us operations generating taxable profits losses company generated approximately us net operating losses us nols tax purposes approximately us nols eligible carryback benefits us tax law resulting benefit company generated approximately us nols us tax purposes resulting benefit december us nols generated utilized recoup past us taxes paid company carryback benefits allowed us tax law fourth quarter due changes tax planning strategies triggered companys intent repatriate earnings act management longer able conclude likely would realize benefit net us deferred tax assets therefore general valuation allowance net us deferred tax assets established december impact income tax expense providing valuation allowance us net deferred tax assets difference income taxes based us statutory tax rate companys income tax expense years ending december due following income tax expensebenefit us statutory rate increasedecrease taxes resulting lower rates jurisdictions net federal tax repatriated foreign earnings act net credits us nol tax benefit recorded provision valuation allowance net us deferred tax assets nondeductible litigation reserves reserves tax litigation research tax credit state income tax permanent differences net income tax effective tax rate table contents notes consolidated financial statements continued lower rates jurisdictions net primarily attributable certain employment capital investment actions taken company result income manufacturing activities jurisdictions subject lower tax rates least december company total deferred tax assets respectively deferred tax liabilities respectively reclassification certain us amounts deferred tax assets liabilities made conform current year presentation valuation allowance net us deferred tax assets established december valuation allowances recorded deferred tax assets december respectively significant deferred tax liabilities december depreciation differences respectively benefit plans respectively net consolidated income tax paymentsrefunds exclusive payments related tax audits discussed respectively december companys us federal income tax returns audited tax contingencies recorded address potential exposures involving tax positions taken could challenged taxing authorities potential exposures result varying application statutes rules regulations interpretations including intercompany terms cross border arrangements affiliates management believes intercompany terms based upon sound economic facts circumstances utilization cash held foreign subsidiaries investment us property companys estimate accrual tax contingencies contains assumptions based past experiences judgments potential actions taxing jurisdictions reasonably possible ultimate resolution tax matters may materially greater less amount accrued october irs auditors asserted reports company liable additional tax tax years reports allege two interest rate swaps company entered unrelated party recharacterized loans affiliated companies april company received formal notice deficiency statutory notice irs asserting additional federal income tax due company received bills related matter irs september payment amount income tax interest made september company filed refund claims tax interest irs december company notified february refund claims denied irs company believes complied applicable rules regulations company intends file suit refund full amount tax interest companys existing tax reserves adequate cover abovementioned payments product licenses acquisitions company entered collaboration license agreement toyama chemical co ltd toyama terms agreement company acquired exclusive worldwide rights excluding japan korea china develop use sell garenoxacin toyamas quinolone antibacterial agent currently development connection execution agreement company incurred charge second quarter upfront fee toyama amount expensed reported research development year ended december statements consolidated operations september company announced entered strategic alliance bayer intended enhance companies pharmaceutical resources october us puerto rico company began market sell distribute bayers primary care products including avelox cipro exclusive license agreement company pay bayer substantial royalties products based sales addition company assumed bayers responsibilities us commercialization activities related erectile dysfunction medicine levitra bayers copromotion agreement glaxosmithkline plc company report share levitra results alliance revenue table contents notes consolidated financial statements continued additionally terms agreements bayer also support promotion certain companys oncology products us key european markets defined period time japan upon regulatory approval bayer comarket companys cholesterol absorption inhibitor zetia ezetimibe arrangement include rights future cholesterol combination product agreements bayer provide upfront payment made company licensing rights levitra avelox company receive record deferred revenue related sale zetia copromotion rights bayer deferred revenue begin recognized upon regulatory approval japan certain circumstances zetia receive regulatorymarketing approval japan certain date amount required repaid bayer agreements bayer restrict company marketing certain products us would compete avelox cipro levitra result company expects may need sublicense rights garenoxacin quinolone antibacterial agent company licensed toyama company exploring options regard garenoxacin continue fulfill commitments toyama arrangement including taking product regulatory approval february company acquired assets neogenesis pharmaceuticals approximately neogenesis applies novel screening chemistry technologies discover new drug candidates inventories inventories consisted following december finished products goods process raw materials supplies total inventories inventories valued lastin firstout basis comprised approximately percent total inventories december estimated replacement cost total inventories december respectively shortterm borrowings longterm debt commitments shortterm borrowings general shortterm borrowings consist commercial paper issued us bank loans notes payable commercial paper outstanding december respectively weightedaverage interest rate shortterm borrowings december percent percent respectively credit facilities company two revolving credit facilities totaling billion facilities syndicate major financial institutions recently negotiated facility may billion fiveyear credit facility facility matures may requires company maintain total debt total capital ratio percent second credit facility provides line credit maturity date may requires company maintain total debt total capital ratio percent time company rated baa moodys bbb sp table contents notes consolidated financial statements continued facilities available general corporate purposes considered support companys commercial paper borrowings facilities require compensating balances however nominal commitment fee paid december funds drawn either facilities addition companys foreign subsidiaries approximately available unused lines credit various financial institutions december longterm debt november company issued aggregate principal amount percent senior unsecured notes due aggregate principal amount percent senior unsecured notes due interest payable semiannually net proceeds offering upon issuance notes rated moodys investors service inc moodys creditwatch negative implications standard poors rating services sp interest rates payable notes subject adjustment follows subsequent issuance rating assigned notes moodys changes one ratings set forth interest rate payable series notes increase additional interest rate set forth table similarly rating assigned notes sp changes one ratings set forth table interest rate payable series notes increase additional interest rate set forth table additional interest rate moody rating sp rating baa bbb baa bbb baa bbb baa bb event interest rate notes increase percent initial coupon rates percent percent respectively either moodys sp subsequently upgrades ratings interest rates correspondingly reduced percent percent respectively furthermore interest rate payable particular series notes return percent percent respectively rate adjustment provisions permanently cease apply following downgrade moodys sp respectively moodys sp raise rating respectively better july moodys lowered rating notes baa accordingly interest payable note increased basis points effective december therefore effective december interest rate payable notes due increased percent percent interest rate payable notes due increased percent percent adjustment interest rate payable notes increase companys interest expense annually notes redeemable whole part companys option time redemption price equal greater percent principal amount notes sum present values remaining scheduled payments principal interest discounted using rate treasury notes comparable remaining terms plus basis points notes basis points notes shelf registration may companys shelf registration amended declared effective securities exchange commission sec shelf registered issuance billion various debt equity securities subsequently company issued billion face amount mandatory convertible preferred stock august shelf december principal amount table contents notes consolidated financial statements continued securities remains registered unissued see note shareholders equity additional information preferred stock issuance changes credit ratings february sp downgraded companys senior unsecured debt ratings time sp also lowered companys short term corporate credit commercial paper rating companys sp rating outlook remains negative march sp assigned shelf registration preliminary rating senior unsecured debt preliminary subordinated debt rating bbb april moodys placed companys senior unsecured credit rating watchlist possible downgrade based upon concerns related market share declines litigation risks high degree reliance success vytorin july moodys lowered companys senior unsecured credit rating baa lowered companys senior unsecured shelf registration rating pa pbaa lowered companys subordinated shelf registration rating pbaa pbaa lowered companys cumulative noncumulative preferred stock shelf registration rating pbaa pbaa confirmed companys p commercial paper rating removed company watchlist moodys rating outlook company negative november fitch ratings fitch downgraded companys senior unsecured bank loan ratings commercial paper rating f f companys rating outlook remained negative announcing downgrade fitch noted sales decline companys leading product franchise time intron franchise greater anticipated concerned total company growth reliant performance two key growth drivers zetia remicade near term august fitch affirmed companys senior unsecured rating bank loan rating f commercial paper rating reiterated negative outlook commitments total rent expense amounted future annual minimum rental commitments noncancelable operating leases december follows aggregate minimum lease obligations due thereafter december company commitments totaling related capital expenditures made financial instruments sfas derivative instruments financial hedging activities amended requires derivatives recorded balance sheet fair value accounting standard also provides effective portion qualifying cash flow hedges recognized income hedged item affects income changes fair value derivatives qualify fair value hedges along change fair value hedged risk recognized occur changes fair value derivatives qualify hedge treatment well ineffective portion qualifying hedges recognized income occur risks policy objectives company exposed market risk primarily changes foreign currency exchange rates lesser extent interest rate equity price changes time time company hedge selective foreign currency risks derivatives generally however management deemed cost effective engage formulabased program hedging profits cash flows foreign operations using derivative financial instruments companys foreign subsidiaries purchase significant table contents notes consolidated financial statements continued quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provides natural level protection adverse changes exchange rates furthermore risk adverse exchange rate change mitigated fact companys foreign operations widespread limited basis company hedge selective exposures mitigate interest rate risks company mitigates credit risk derivative instruments dealing counterparties considered financially sound accordingly company anticipate loss nonperformance company enter derivative instruments generate trading profits table presents carrying values estimated fair values companys financial instruments including derivative financial instruments december estimated fair values determined based market prices available dealer quotes carrying estimated carrying estimated value fair value value fair value assets cash cash equivalents shortterm investments longterm investments liabilities shortterm borrowings current portion longterm debt longterm debt interest rate swap contracts longterm investments longterm investments included noncurrent assets primarily consist debt equity securities held nonqualified trusts fund long term employee benefit obligations included liabilities consolidated balance sheets assets used fund related liabilities longterm investments classified available sale carried fair value realized gains sale securities classified available sale proceeds sales totaled respectively realized gains recorded expense income net interest rate swap contracts company interest rate swap arrangement effect counterparty bank subject credit rating triggers arrangement utilizes two long term interest rate swap contracts one foreignbased subsidiary company bank us subsidiary company bank two contracts equal offsetting terms covered master netting arrangement contract involving foreignbased subsidiary permits subsidiary prepay portion future obligation bank contract involving us subsidiary permits bank prepay portion future obligation us subsidiary interest paid prepaid balances parties market rates prepayments totaling billion made contracts december arrangement originally provided event company failed maintain required minimum credit ratings counterparty may terminate transaction designating early termination table contents notes consolidated financial statements continued date earlier months following date notice terminate sps moodys current credit ratings specified minimum march counterparty given company notice terminate december company counterparty mutually agreed amend swap contracts company counterparty agreed phased termination arrangement including repayment prepaid amounts based agreed schedule scheduled terminations associated repayment prepaid amounts begin later march end later january addition amended agreement month grace period previously applied event counterparty gives notice termination result companys failure maintain required minimum credit ratings extended january event counterparty gives company termination notice provision scheduled terminations associated payments continue according agreed repayment schedule time delivery termination notice january provisions original arrangement also allowed counterparty give month notice terminate transaction th anniversary transaction november companys credit ratings least moodys sp eliminated place company accepted new credit trigger provides counterparty may terminate transaction company fail maintain longterm us dollar denominated senior unsecured indebtedness rating least bbb sp baa moodys termination provision would later november days date company receives notice terminate company fail meet minimum credit requirement resulting early termination provision scheduled swap terminations associated payments continue termination date company may option accelerate scheduled terminations associated payments nominal fee february companys foreign based subsidiary us subsidiary gave notice counterparty terminate arrangement accordingly prepaid amounts repaid respective obligor company repay us obligation funds repatriated american jobs creation act company utilized interest rate swaps part international cash management strategy notional principal arrangement notional principal arrangement arrangements year terms fair value swaps liability december may interest rate swaps related swap arrangements terminated impact companys statements consolidated operations material shareholders equity company authorized shares preferred stock consists preferred shares designated series junior participating preferred stock preferred shares designated mandatory convertible preferred stock preferred shares whose designations yet determined mandatory convertible preferred stock august company issued shares mandatory convertible preferred stock preferred stock face value billion net proceeds company billion deducting commissions discounts underwriting expenses proceeds used general corporate purposes including reduction commercial paper borrowings table contents notes consolidated financial statements continued mandatory conversion date shares september date share automatically convert common shares company depending average closing price companys common shares period immediately preceding mandatory conversion date defined prospectus preferred shareholders may elect convert time prior september minimum conversion ratio common shares per share preferred stock additionally time prior mandatory conversion date closing price companys common shares exceeds least trading days within period consecutive trading days company may elect cause conversion less preferred stock outstanding minimum conversion ratio common shares preferred share preferred stock accrues dividends annual rate percent shares outstanding dividends cumulative date issuance extent company legally permitted pay dividends board directors declares dividend payable company pay dividends dividend payment date dividend payment dates march june september december first dividend paid december treasury stock summary treasury share transactions year ended december follows hares milli ons share balance january shares issued stock incentive plans share balance december preferred share purchase rights company preferred share purchase rights outstanding attached presently trade companys common shares exercisable rights become exercisable person group acquires percent companys common stock announces tender offer completed would result ownership person group percent companys common stock person group acquire percent companys outstanding common stock merger business combination transaction right entitle holder acquirer purchase common shares scheringplough market value twice exercise price right exercise price rights following acquisition person group beneficial ownership percent less percent companys common stock board directors may call exchange rights rights owned acquirer whole part exchange ratio one common share one twohundredth share series junior participating preferred stock per right also prior acquisition person group beneficial ownership percent companys common stock rights redeemable per right option board directors rights expire july unless earlier redeemed exchanged board directors also authorized reduce percent thresholds referred less greater sum percent largest percentage outstanding shares common stock known company beneficially owned person group affiliated associated persons ii percent except following acquisition person group beneficial ownership percent companys common stock reduction may adversely affect interests holders rights table contents notes consolidated financial statements continued insurance coverage company maintains insurance coverage deductibles selfinsurance management believes adequate needs current circumstances coverage reflects market conditions including cost availability existing time written relationship insurance coverage selfinsurance varies accordingly result recent external events availability insurance become restrictive management considers impact changes continually assesses best way provide insurance needs future company selfinsures higher proportion risk past especially relates products liability stock incentive plans terms companys stock incentive plan approved companys shareholders million companys common shares may granted stock options awarded deferred stock units officers certain employees company december december million options deferred stock units remain available future year grants stock incentive plan option exercise prices equal market price common shares grant dates options expire later years date grant standard options granted threeyear vesting term granted prior generally oneyear vesting term option grants vest longer periods ranging three nine years deferred stock units payable equivalent number common shares shares distributable single installment three five equal annual installments generally commencing three years date award following table summarizes stock option activity past three years current prior plans approved companys shareholders weighted weighted weighted number average number average number average exercise exercise exercise options price options price options price num ber options illions outstanding january granted exercised canceled expired outstanding december exercisable december summarized information stock options outstanding exercisable december follows standing exercisable weighted average weighted weighted number remaining average number average term exercise exercise exercise price range options years price options price numbe r options millions table contents notes consolidated financial statements continued company awarded deferred stock units totaling million million million respectively retirement plans postretirement benefits company defined benefit pension plans covering eligible employees us certain foreign countries company provides postretirement health care benefits eligible us retirees dependents measurement date majority plans december net pension expense compared net pension expense estimated onehalf percent reduction expected long term rate return consolidated plan assets would increase pension expense approximately estimated onehalf percent reduction discount rate would increase pension expense approximately also december company unrecognized net actuarial loss gains losses arise primarily plan assets earning less longterm expected rate return changes pension discount rates gains future offset net unrecognized loss amortization losses would ultimately increase annual pension expense approximately components net pension postretirement benefits expense follows pos tret ire ment alth retirement plans care benefits service cost interest cost expected return plan assets amortization net termination benefits curtailment settlement net pension postretirement benefits expense termination benefits curtailment settlement costs primarily relate matters discussed note special charges table contents notes consolidated financial statements continued components changes benefit obligations follows post tirem ent health care retirement plans benefits benefit obligations january service cost interest cost assumption changes effects exchange rate changes benefits paid actuarial losses plan amendments medicare act subsidy termination benefits curtailment settlement benefit obligations december benefit obligations funded plans benefit obligations funded plans termination benefits curtailment settlement costs primarily relate matters discussed note special charges components changes plan assets follows post tirem ent health care retirement plans benefits fair value plan assets primarily stocks bonds january actual gain loss plan assets contributions effects exchange rate changes benefits paid fair value plan assets december plan assets overfunded plans plan assets underfunded plans addition plan assets indicated december securities respectively held nonqualified trusts designated provide pension benefits certain underfunded plans december accumulated benefit obligation retirement plans respectively aggregated accumulated benefit obligation fair value plan assets retirement plans accumulated benefit obligation excess plan assets respectively december respectively december table contents notes consolidated financial statements continued contributions retirement plans postretirement health care benefits currently estimated approximately following benefit payments reflect expected future service appropriate expected paid postret irement retirement health care plans benefits years expected benefit payments reduced expected subsidy payments medicare act respectively following reconciliation funded status plans companys balance sheet post tirem ent health care retirement plans benefits benefit obligations excess plan assets unrecognized net transition assets unrecognized prior service costs unrecognized net actuarial loss net assets december amounts recognized balance sheet consist pos tret irem ent health care retirement plans benefits prepaid benefit cost accrued benefit cost intangible assets accumulated comprehensive income net assets december december companys additional minimum pension liability respectively primarily related domestic retirement plans resulted adjustment accumulated comprehensive income net tax respectively table contents notes consolidated financial statements continued consolidated weightedaverage assumptions used determine benefit obligations december post reti reme nt retirement health care plans benefits discount rate rate increase future compensation na na consolidated weightedaverage assumptions used determine net cost years ended december post reti reme nt retirement health care plans benefits discount rate longterm expected rate return plan assets rate increase future compensation na na longterm expected rate return plan assets derived proportionally return assumptions determined major asset classes principally equities fixed income real estate return expectations asset classes based largely assumptions economic growth inflation supported longterm historical data weightedaverage assumed health care cost inflation rate used postretirement measurement purposes percent trending percent percent increase assumed health care cost trend rate would increase combined postretirement service interest cost post retirement benefit obligation percent decrease assumed health care cost trend rate would decrease combined postretirement service interest cost postretirement benefit obligation accordance fasb staff position accounting disclosure requirements related medicare prescription drug improvement modernization act medicare act company began accounting effect federal subsidy medicare act third quarter result companys accumulated benefit obligation postretirement benefits reduced companys net postretirement benefits expense reduced reduction postretirement benefits expense consists reductions service cost interest cost net amortization respectively plan assets fair value asset allocation consolidated retirement plans december target allocation follows pe rcent age f plan assets target december allocation asset category equity securities debt securities real estate total table contents notes consolidated financial statements continued asset allocation postretirement health care benefit trusts december target allocation follows pe rcent age f plan assets target december allocation asset category equity securities debt securities total companys investments related plans broadly diversified consisting primarily equities fixed income securities objective generating longterm investment returns consistent acceptable level overall portfolio market value risk company defined contribution profitsharing plan covering substantially fulltime domestic employees completed one year service annual contribution determined formula based companys income shareholders equity participants compensation profit sharing expense totaled profit sharing contribution determined formula described company longer makes contributions plan company began make contributions existing defined contribution savings plan equal percent eligible employee earnings plus matching percent eligible employee earnings based employee contributions plan total company contributions plan consent decree may scheringplough announced reached agreement fda consent decree resolve issues involving scheringploughs compliance current good manufacturing practices cgmp certain manufacturing facilities new jersey puerto rico us district court district new jersey approved entered consent decree may terms consent decree scheringplough agreed pay total us government two equal installments first installment paid may second installment paid may previously reported scheringplough accrued provision consent decree fourth quarter consent decree requires scheringplough complete number actions including comprehensive cgmp work plans scheringploughs manufacturing facilities new jersey puerto revalidation finished drug products bulk active pharmaceutical ingredients manufactured facilities decree scheduled completion dates december cgmp work plans september revalidation programs bulk active pharmaceutical ingredients december revalidation programs finished drugs cgmp work plans contain number significant steps whose timely satisfactory completion subject payments thousand per business day deadline missed payments may exceed years payments subject overall cap general timely satisfactory completions revalidations subject payments thousand per business day deadline missed subject caps described however product scheduled revalidation certified validated last date validation schedule fda may assess payment percent net domestic sales uncertified product validation certified general product scheduled revalidation table contents notes consolidated financial statements continued consent decree certified within six months scheduled date scheringplough must cease production product certification obtained completion significant steps work plans completion revalidation programs subject thirdparty expert certification well fdas acceptance certification consent decree provides scheringplough believes may able meet deadline scheringplough right upon showing good cause request extensions deadlines connection cgmp work plans revalidation programs however guarantee fda grant requests although scheringplough believes made significant progress meeting obligations consent decree possible scheringplough may fail complete significant step revalidation prescribed deadline thirdparty expert may certify completion significant step revalidation fda may disagree experts certification significant step revalidation case possible fda may assess payments described scheringplough would expense payments assessed decree incurred segment information company three reportable segments prescription pharmaceuticals consumer health care animal health segment sales profit data follow consistent companys current management reporting structure prescription pharmaceuticals segment discovers develops manufactures markets human pharmaceutical products consumer health care segment develops manufactures markets otc foot care sun care products animal health segment discovers develops manufactures markets animal health products net sales segment ear e nde dece mbe r prescription pharmaceuticals consumer health care animal health consolidated net sales profit segment ear e nded dece mber prescription pharmaceuticals consumer health care animal health corporate consolidated lossprofit tax corporate includes interest income expense foreign exchange gains losses headquarters expenses special charges miscellaneous items accounting policies used segment reporting described note summary significant accounting policies corporate includes special charges including employee termination costs well asset impairment charges closure costs primarily related exit table contents notes consolidated financial statements continued small european researchanddevelopment facility see note special charges additional information estimated charges relate reportable segments follows prescription pharmaceuticals consumer health care animal health corporate corporate includes special charges including employee termination costs provision increase litigation reserves asset impairment charges see note special charges additional information estimated charges relate reportable segments follows prescription pharmaceuticals consumer health care animal health corporate net sales major product prescription pharmaceuticals remicade clarinexaerius nasonex pegintron temodar integrilin claritin rx intron rebetol subutex elocon caelyx pharmaceutical consumer health care otc includes otc claritin sales respectively foot care sun care animal health consolidated net sales net sales geographic area united states europe canada latin america pacific area asia consolidated net sales table contents notes consolidated financial statements continued company subsidiaries countries outside us single foreign country except france italy japan accounted percent consolidated net sales past three years net sales presented geographic area companys customers located total international sales france italy japan net sales customer mckesson corporation amerisourcebergen corporation single customer except mckesson corporation amerisourcebergen corporation two major pharmaceutical health care products distributors accounted percent consolidated net sales past three years longlived assets geographic location united states ireland singapore puerto rico total longlived assets shown geographic location primarily property sales products comprising percent companys us international sales year ended december follows u internat ional remicade clarinex otc claritin nasonex scheringplough net sales include sales vytorin zetia marketed partnership merck company accounts joint venture equity method accounting see note equity income cholesterol joint venture company disaggregate assets segment basis internal management reporting therefore information presented table contents notes consolidated financial statements continued legal environmental regulatory matters background company involved various claims investigations legal proceedings company records liability contingencies probable liability incurred amount reasonably estimated company adjusts liabilities contingencies reflect current best estimate probable loss minimum liability case may best estimate determinable company records minimum amount within probable range liability expected insurance recoveries considered determining amounts recorded liabilities environmentalrelated matters company believes loss contingency reasonably possible rather probable amount loss estimated liability recorded however liability reasonably possible disclosure loss contingency made company reviews status matters discussed remainder note ongoing basis time time company may settle otherwise resolve matters terms conditions management believes best interests company resolution items discussed remainder note individually aggregate could material adverse effect companys results operations cash flows financial condition resolution including settlements matters types set forth remainder note particular investigations frequently involve fines penalties amount would material financial condition cash flows results operations resolution matters may also involve injunctive administrative remedies would adversely impact business exclusion government reimbursement programs turn would material adverse impact business future financial condition cash flows results operations assurances company prevail matters discussed remainder note settlements reached acceptable terms including scope release provided absence injunctive administrative remedies would adversely impact business exclusion government reimbursement programs amounts exceed amounts reserved even acceptable settlement reached assurance investigations litigations commenced raising similar issues potentially exposing company additional material liabilities outcome matters discussed investigations could include commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs total liabilities reserved reflect estimate case investigations estimate minimum liability final settlement adjudication matters could possibly less could materially exceed liabilities recorded financial statements could material adverse impact companys financial condition cash flows operations company predict timing resolution matters outcomes except matters discussed remainder note recorded liabilities contingencies december related expenses incurred year ended december material opinion management based advice legal counsel ultimate outcome matters except matters discussed remainder note material impact companys results operations cash flows financial condition table contents notes consolidated financial statements continued company increased litigation contingent liabilities result investigations us attorneys office district massachusetts us attorneys office eastern district pennsylvania noted pennsylvania investigation settled payments made company previously recorded liability approximately related massachusetts investigation reasonably possible settlement massachusetts investigation could involve amounts materially excess accrual could material adverse impact companys financial condition cash flows operations required us gaap since company reasonably estimate potential final resolution company recognized estimated minimum liability massachusetts investigation patent matters dr scholls freeze away patent july orasure technologies filed action us district court eastern district pennsylvania alleging patent infringement scheringplough healthcare products sale dr scholls freeze away wart removal product complaint seeks permanent injunction unspecified damages including treble damages freeze away product launched march net sales product totaled approximately investigations pennsylvania investigation july scheringplough corporation us department justice us attorneys office eastern district pennsylvania announced settlement previously disclosed investigation office settlement schering sales corporation indirect wholly owned subsidiary scheringplough corporation pled guilty single federal criminal charge concerning payment managed care customer connection settlement aggregate settlement amount fines damages scheringplough corporation credited previously paid additional medicaid rebates leaving net settlement amount plus interest paid schering sales corporation excluded participating federal health care programs settlement affect ability scheringplough corporation participate programs scheringplough corporation entered fiveyear corporate integrity agreement office inspector general department health human services scheringplough corporation agreed implement specific measures promote compliance regulations issues marketing failure comply result financial penalties company predict impact settlement outstanding investigations massachusetts investigation us attorneys office district massachusetts investigating broad range companys sales marketing clinical trial practices programs along warrick pharmaceuticals warrick companys generic subsidiary scheringplough disclosed connection investigation may schering corporation wholly owned significant operating subsidiary scheringplough received letter boston target letter office advising schering corporation including subsidiaries divisions target federal criminal investigation respect four areas providing remuneration drug samples clinical trial grants items services value managed care organizations physicians others induce purchase schering pharmaceutical products sale misbranded unapproved drugs company understands mean drugs promoted indications approval us fda obtained socalled offlabel uses table contents notes consolidated financial statements continued submitting false pharmaceutical pricing information government purposes calculating rebates required paid medicaid program failing include prices product manufactured sold private label arrangement managed care customer well prices free nominally priced goods provided customer induce purchase schering products document destruction obstruction justice relating governments investigation target defined department justice guidelines person prosecutor grand jury substantial evidence linking commission crime judgment prosecutor putative defendant us attorneys manual section company implemented certain changes sales marketing clinical trial practices continuing review practices ensure compliance relevant laws regulations company cooperating investigation see information prior increases liabilities reserved financial statements including relation investigation litigation charges note special charges additional information reserves potential impacts outcome investigation background section note company previously recorded liability approximately related investigation reasonably possible settlement investigation could involve amounts materially excess accrual could material adverse impact companys financial condition cash flows operations required us gaap since company reasonably estimate potential final resolution company recognized estimated minimum liability nitrodur investigation august company received civil investigative subpoena issued office inspector general us department health human services seeking documents concerning companys classification nitrodur medicaid rebate purposes companys use nominal pricing bundling product sales company cooperating investigation appears subpoena one number addressed pharmaceutical companies concerning inquiry issues relating payment government rebates pricing matters awp investigations company continues respond investigations department health human services department justice certain states industry company practices regarding average wholesale price awp investigations include department justice review merits federal action filed private entity behalf us us district court southern district florida well investigation us attorneys office district massachusetts regarding inter alia whether awp set pharmaceutical companies certain drugs improperly exceeds average prices paid dispensers consequence results unlawful inflation certain government drug reimbursements based awp march company received subpoena massachusetts attorney generals office seeking documents concerning use awp pricing andor marketing practices company also responded subpoenas attorney general california concerning matters company cooperating investigations outcome investigations could include imposition substantial fines penalties injunctive administrative remedies prescription access litigation december prescription access litigation project pal bostonbased group formed litigate drug companies filed class action suit federal court massachusetts company september consolidated complaint filed court result coordination multidistrict litigation panel federal court awp cases throughout country consolidated complaint alleges company warrick pharmaceuticals table contents notes consolidated financial statements continued companys generic subsidiary conspired providers defraud consumers reporting fraudulently high awps prescription medications reimbursed medicare thirdparty payers complaint seeks declaratory judgment unspecified damages including treble damages included litigation described prior paragraph lawsuits allege company warrick reported inflated awps prescription pharmaceuticals thereby caused state federal entities thirdparty payers make excess reimbursements providers actions also allege company warrick failed report accurate prices medicaid rebate program thereby underpaid rebates states cases filed state attorneys general also seek recover behalf citizens state entities located state excess payments result inflated awps actions began october brought state attorneys general private plaintiffs nonprofit organizations employee benefit funds allege violations federal state law including fraud antitrust racketeer influenced corrupt organizations act rico claims first quarter company warrick among five groups companies put accelerated discovery track proceeding addition warrick company defendants number lawsuits state courts actions generally brought states andor political subdivisions seek unspecified damages including treble punitive damages securities class action litigation february company stated press release fda conducting inspections companys manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices primarily relating production processes controls procedures next day february lawsuit filed us district court district new jersey company certain named officers alleging violations sections b securities exchange act rule b promulgated thereunder additional lawsuits tenor followed complaints consolidated one action us district court district new jersey lead plaintiff florida state board administration appointed court july october consolidated amended complaint filed alleging violations described second sentence paragraph purporting represent class shareholders purchased shares company stock may february complaint seeks compensatory damages behalf class companys motion dismiss consolidated amended complaint denied may october court certified shareholder class discovery ongoing addition lawsuits described immediately preceding paragraph two lawsuits filed us district court district new jersey two lawsuits filed new jersey state court company nominal defendant certain officers directors former director seeking damages behalf company including disgorgement trading profits made defendants allegedly obtained basis material nonpublic information complaints four lawsuits relate issues described companys february press release allege failure disclose material information breach fiduciary duty directors one federal court lawsuits also includes allegations related investigations us attorneys offices eastern district pennsylvania district massachusetts ftcs administrative proceeding company lawsuit state texas warrick companys generic subsidiary us attorneys investigations ftc proceeding described herein texas litigation described previously filed ks qs lawsuits shareholder derivative action purports assert claims behalf company demand made board directors decision made whether company pursue claims august plaintiffs new jersey state court shareholder derivative actions moved dismiss voluntarily complaints actions motions granted two shareholder derivative actions pending us district court district new jersey consolidated one action table contents notes consolidated financial statements continued early stages january company received demand letter dated december law firm involved derivative actions described behalf shareholder also involved derivative actions demanding board directors bring claims behalf company based allegations substantially similar alleged derivative actions january board directors adopted board resolution establishing evaluation committee consisting three directors investigate review analyze facts circumstances surrounding allegations made demand letter consolidated amended derivative action complaint described reserving full board authority discretion exercise business judgment respect proper disposition demand committee engaged independent outside counsel advise issued report findings investigation independent directors board late october report determined shareholder demand refused finding liability part officers directors november full board adopted recommendation evaluation committee company defendant number purported nationwide state class action lawsuits plaintiffs seek refund purchase price laxatives phenylpropanolaminecontaining coughcold remedies ppa products purchased pharmaceutical manufacturers codefendants lawsuits general plaintiffs claim would purchased would paid less products known certain defects medical risks attendant use litigation claims relating companys ppa products courts national class action suit several state class action suits denied certification dismissed suits similar application deny class certification new jersey remaining statewide class action suit involving company granted september approximately individual lawsuits relating laxative products ppa products recalled albuterolvancerilvancenase inhalers also pending company seeking recovery personal injuries death number lawsuits punitive damages claimed litigation filed us district court new jersey alleging company richard jay kogan companys employee savings plan plan administrator several current former directors certain corporate officers breached fiduciary obligations certain participants plan complaint seeks damages amount losses allegedly suffered plan complaint dismissed june plaintiffs appeal pending lawsuit filed new jersey superior court chancery division union county alleging breach fiduciary duty outside directors relating companys receipt boston target letter described investigations section note dismissed september upon consent parties antitrust ftc matters kdur kdur scheringploughs longacting potassium chloride product supplement used cardiac patients scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle related generic versions kdur lederle upsher smith filed abbreviated new drug applications andas april ftc started administrative proceeding scheringplough upshersmith lederle complaint alleged anticompetitive effects settlements june administrative law judge overseeing case issued decision patent litigation settlements complied law respects dismissed claims company ftc staff appealed decision full commission december full commission issued opinion reversed decision ruled settlements violate antitrust laws full commission issued cease desist order imposing various injunctive restraints opinion filed march federal court appeals set aside commission ruling vacated cease desist order table contents notes consolidated financial statements continued following commencement ftc administrative proceeding alleged class action suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits allege essentially facts claim violations federal state antitrust laws well state statutory andor common law causes action suits seek unspecified damages discovery ongoing sec inquiries related litigation september sec company announced settlement sec enforcement proceeding company richard jay kogan former chairman chief executive officer regarding meetings held investors week september communications without admitting denying allegations company agreed commit future violations regulation fd related securities laws paid civil penalty million mr kogan paid civil penalty thousand september lawsuit filed new jersey superior court union county richard jay kogan companys outside directors alleging breach fiduciary duty fraud deceit negligent misrepresentation relating alleged disclosures made meetings mentioned company removed case federal court case remanded state court company filed motion dismiss matters emea pharmacovigilance matter pharmacovigilance inspections officials british french medicines agencies conducted request european agency evaluation medicinal products emea serious deficiencies reporting processes identified scheringplough continues work action plan rectify deficiencies provides regular updates emea company know action emea national authorities take response findings possible actions include inspections demands improvements reporting systems criminal sanctions company andor responsible individuals changes conditions marketing authorizations companys products biopharma contract dispute biopharma srl filed claim civil court rome july docket th chamber certain scheringplough subsidiaries matter relates certain contracts dated november distribution supply agreements biopharma scheringplough subsidiary distribution scheringplough generic products manufactured biopharma hospitals pharmacists france july letter agreement among biopharma scheringplough subsidiary medipha sante sa appointing medipha distribute products france biopharma alleges scheringplough fulfill duties contracts tax matters october irs auditors asserted reports company liable additional tax tax years reports allege two interest rate swaps company entered unrelated party recharacterized loans affiliated companies april company received formal notice deficiency statutory notice irs asserting additional federal income tax due company received bills related matter irs september payment amount income tax interest made september company filed refund claims tax interest irs december company notified february refund claims denied irs company believes complied applicable rules regulations intends file suit refund full amount tax interest companys tax reserves adequate cover abovementioned payments table contents notes consolidated financial statements continued environmental company responsibilities environmental cleanup various state local federal laws including comprehensive environmental response compensation liability act commonly known superfund several superfund sites equivalent sites state law company alleged potentially responsible party prp except site separately disclosed company believes remote time material liability relation sites company estimates obligations cleanup costs superfund sites based information obtained federal environmental protection agency epa equivalent state agency andor studies prepared independent engineers probable costs paid prps company records liability environmental assessments andor cleanup probable loss incurred amount reasonably estimated table contents report independent registered public accounting firm board directors shareholders scheringplough corporation audited accompanying consolidated balance sheets scheringplough corporation subsidiaries company december related consolidated statements operations shareholders equity cash flows three years period ended december audits also included financial statement schedule listed item financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position scheringplough corporation subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion financial statement schedule considered relation basic consolidated financial statements taken whole presents fairly material respects information set forth therein also audited accordance standards public company accounting oversight board united states effectiveness companys internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated march expressed unqualified opinion managements assessment effectiveness companys internal control financial reporting unqualified opinion effectiveness companys internal control financial reporting deloitte touche llp parsippany new jersey march table contents scheringplough corporation subsidiaries quarterly data unaudited thre e onths end ed march june september december ollars illions except per share fig ures net sales cost sales gross profit selling general administrative research development income expense net special charges equity incomeloss cholesterol joint venture lossincome income taxes income tax benefitexpense net lossincome dividends preferred shares net lossincome available common shareholders diluted lossearnings per common share basic lossearnings per common share dividends per common share common share prices high low average shares outstanding diluted eps millions average shares outstanding basic eps millions see special charges footnote notes consolidated financial statements additional information relating special charges companys common shares listed principally traded new york stock exchange approximate number holders record common shares january item changes disagreements accountants accounting financial disclosure applicable item controls procedures management including chief executive officer chief financial officer evaluated companys disclosure controls procedures end period covered k concluded companys disclosure controls procedures effective also concluded changes companys internal control financial reporting occurred companys recent fiscal quarter materially affected reasonably likely materially affect companys internal control financial reporting table contents managements report internal control financial reporting management scheringplough corporation responsible establishing maintaining adequate internal control financial reporting schering ploughs internal control system designed provide reasonable assurance companys management board directors regarding preparation fair presentation published financial statements internal control systems matter well designed inherent limitations therefore even systems determined effective provide reasonable assurance respect financial statement preparation presentation scheringploughs management assessed effectiveness companys internal control financial reporting december making assessment management used criteria set forth committee sponsoring organizations treadway commission coso internal control integrated framework based assessment management believes december companys internal control financial reporting effective based criteria scheringploughs independent auditors deloitte touche llp issued attestation report managements assessment companys internal control financial reporting report follows table contents report independent registered public accounting firm board directors shareholders scheringplough corporation audited managements assessment included accompanying managements report internal control financial reporting schering plough corporation subsidiaries company maintained effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion managements assessment opinion effectiveness companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe audit provides reasonable basis opinions companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion managements assessment company maintained effective internal control financial reporting december fairly stated material respects based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission table contents also audited accordance standards public company accounting oversight board united states consolidated financial statements financial statement schedule year ended december company report dated march expressed unqualified opinion financial statements financial statement schedule deloitte touche llp parsippany new jersey march table contents part iii item directors executive officers registrant information concerning directors nominees directors set forth captions proposal one election directors stock ownership companys proxy statement annual meeting shareholders april incorporated herein reference information required executive officers included part filing caption executive officers registrant companys board directors determined company least one audit committee financial expert serving audit committee financial expert arthur f weinbach independent defined new york stock exchange listing standards restrictive scheringplough board independence standard found scheringplough corporate governance guidelines available web site also included proxy statement required rule ab securities exchange act amended company adopted standards global business practices applicable employees including chief executive officer chief financial officer controller standards global business practices incorporated reference exhibit k written copy standards global business practices well directors code conduct ethics provided charge writing corporate secretary scheringplough corporation galloping hill road mail stop k kenilworth new jersey also documents available scheringplough web site wwwscheringploughcom see investor relations corporate governance codes conduct item executive compensation executive compensation information set forth caption executive compensation companys proxy statement annual meeting shareholders april incorporated herein reference item security ownership certain beneficial owners management related stockholder matters information concerning security ownership certain beneficial owners management set forth caption stock ownership companys proxy statement annual meeting shareholders april incorporated herein reference equity compensation plan information following information relates plans equity securities company may issued employees directors company plans equity securities may issued nonemployees except stock incentive plan predecessor plans certain stock options may transferable family members employeeoptionee related trusts table contents column c olumn b column c number securities remaining available weightedaverage future issuance equity number securities issued exercise price compensation plans upon exercise outstanding outstanding options excluding securities reflected plan category options warrants rights warrants rights column equity compe nsation plans approved security holders stock incentive plan predecessor plans equity compensation plans approved security holders directors stock award plan na na scheringplough ireland share purchase scheme na na nonplan inducement awards approved security holders restricted shares na total plan provides annual grant shares common stock nonemployee director directors may defer awards stock units pay shares common stock deferral period ends plan permits employees reside ireland enjoy tax advantages christmas bonus pay passed trustee trustee purchases shares common stock open market allocates shares employees accounts irish pounds employee may deferred year employees may sell withdraw shares allocated accounts two three years represents restricted shares awarded pursuant restricted shares agreements outside equity compensation plan adopted company mr hassan awarded restricted shares upon commencement employment april ms cox awarded restricted shares upon commencement employment may awards restricted shares vest upon third anniversary award date nonplan awards authorized compensation committee board approved stockholders company item certain relationships related transactions information concerning certain relationships related transactions set forth caption certain transactions companys proxy statement annual meeting shareholders april incorporated herein reference item principal accountant fees services information concerning principal accountant fees services set forth caption proposal two ratification designation independent registered public accountants companys proxy statement annual meeting shareholders april incorporated herein reference table contents part iv item